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Abstract
Early detection and diagnosis o f cancer has a significant impact on cancer 
specific mortality as shown in randomised screening trials for breast, colon 
and lung cancer. However, current screening tests have limitations as they 
reduce cancer specific mortality for breast, colon and lung cancer by only 
24%, 16% and 20% respectively, and partly as a result cancer continues to be 
one o f the common causes o f death in the developed world(Aberle et al, 2011; 
Hardcastle et al, 1996; Larsson et al, 1996). One o f the other problems 
associated with current screening tests is patient compliance (mammography, 
colonoscopy and CT) (Jonnalagadda et al, 2012; Maurer, 1995; Pooler et al, 
2012).
Diagnosing cancers with a blood test by identifying tumour associated 
antibodies in serum is a novel method which may allow the identification of 
early stage cancers and hopefully it would have greater patient acceptability. 
These tumour associated antibodies represent an indirect amplified signal 
generated as a response by the immune system to tumour associated antigens 
secreted early on in development o f cancer.
One o f the common limitations o f many autoantibody studies is the selection 
o f appropriate controls -  or the lack o f such. One common problem is the use 
o f limited number o f normal individuals without cancer as controls, the data 
from which may not be representative o f the normal population as a whole 
(Stockert et al, 1998). In addition not only the numbers o f controls are often 
incorrect but also the age o f the controls. Many studies report using ‘blood
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donors’ as controls(Guy et al, 1981) and clearly for most tumour types this 
involves both a younger population and also a relatively health population 
which may not always be reflective o f  the individuals to be screened (e.g. 
compare heavy smokers).
We hypothesised that autoantibody response to cancer associated antigens 
may alter with demographics (age, sex, and smoking) and the aim of our study 
was to identify the spectrum of response o f tumour associated antigens in a 
range o f demographic groups within the normal population o f the East 
Midlands.
EarlyCDT-Lung™ is a simple commercial blood test which is reported to aid 
the early detection o f lung cancer. The technology was initially developed in 
the laboratories o f the Division o f Breast Surgery and subsequently underwent 
further development by the university spinout company, Oncimmune. 
EarlyCDT-Lung initially measured autoantibodies (AAbs) to six cancer 
associated antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexinl, and SOX2) 
and was reported to identify up to 40% o f lung cancers, at both at eariy- and 
late-stage disease(Boyle et al, 2011; Chapman et al, 2012; Chapman et al, 
2011; Lam et al, 2011; Macdonald et al, 2012a; Macdonald et al, 2012b; 
Murray et al, 2010).The initial technical (Murray et al 2010) and clinical 
(Boyle et a;l 2011; Lam et al 2011) validation studies matched high risk 
individuals to every lung cancer patient. Controls were individually matched to
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a patient with lung cancer by age, gender and smoking history. As the 6 
antigen panel had been developed and validated (Boyle et al, 2011; Murray et 
al, 2010) it was decided to proceed to assess the level o f autoantibodies across 
the population and in particular to look at differences by gender and different 
decades o f life. We used a semi-automated Enzyme linked immunosorbent 
assays (ELISA) to run the serum samples collected from individuals with no 
previous history o f cancer.
Informed consent was taken prior to a detailed health questionnaire and then a 
blood sample by standard venipunture. The information acquired in the 
questionnaire included age, gender, smoking history, any autoimmune disease 
and family history o f cancer.
Serum samples used in this thesis were collected from 2065 individuals. Male 
to female ratio was 1: 2.6(566:1487). Ratio o f smoker versus ex-smokers 
versus non-smoker was 1: 2.4: 3.8 (285:672:1096). There was a fall in the 
number o f smokers with increasing decade o f life. The proportion o f smokers 
and ex-smokers versus non-smokers remained approximately the same in both 
genders. Almost half the patients (964) had family history o f some form of 
cancer. One hundred and eighty six subjects (9%) had personal history o f 
autoimmune disease.
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Analysis o f autoantibody levels revealed a small but steady increase with 
increasing age for 4 out o f the 6 antigens (p53, NY-ESO-1, CAGE and GBU4- 
5). Except for CAGE, there was no significant difference in mean optical 
densities between males and females. For CAGE, when analysis o f variance 
was used to adjust for run differences, there was no significant difference in 
mean optical densities between males and females.
Autoantibody response to all 6 cancer related antigens were consistently low in 
smokers. The rise in autoantibody response was more in the ex-smoker group 
compared to the other two groups suggesting the possibility o f rebound effect 
when smoking is stopped. It reached statistical significance except in case o f 
NY-ESO-1. Age matched analysis were done, and the differences were 
statistically significant for p53, GBU 4-5 and Annexinl. To explore further the 
"rebound" hypothesis further, the year o f quitting for ex-smokers were 
extracted from the database. Any association between AAb levels and time 
lapse since quitting might provide support to this hypothesis. Very little 
difference was seen for most antigens back to 1970, but decades before that 
there was an observed increase in the mean AAb level for all antigens except 
SOX2. Further work would be required to establish such a rebound effect.
Family history and history o f autoimmune disease did not have a significant 
impact on autoantibody levels.
Analysis o f autoantibody levels in a large cohort o f the normal population o f 
the East Midlands revealed that age has a small but significant influence on the 
serum levels o f certain autoantibodies to cancer related antigens. However,
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this could be confounded by the fact that incidence o f cancer also increases 
with age, and would need further investigation and in particular longer follow­
up o f patients who have given blood in this research study to see which 
individuals have developed cancer.
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Chapter 1. Introduction
1.1 Screening for cancer: current modalities and future 
opportunities
Randomised controlled trials o f screening for breast, colon, lung and prostate 
cancer have shown that early diagnosis has a significant impact on the 
mortality from each o f these tumour types (Aberle et al, 2011; Hardcastle et al, 
1996; Larsson et al, 1996; Schroder et al, 2012).
In spite o f the advances in screening for each o f these types o f cancer there 
remains significant opportunities to further improve on early detection since 
screening in these four types o f cancer reduce cancer specific mortality 
between 15%(Hardcastle et al, 1996) and 24%(Larsson et al, 1996). It should 
be acknowledged too that the improvement in cancer specific mortality has not 
all been due to screening and early detection. It has been shown for breast and 
colon cancer in particular through randomized trials o f adjuvant therapy that 
systemic therapies have also made a significant impact on cancer specific 
mortality in these diseases(Boccardo, 2008; Gray et al, 2007; Sakamoto et al, 
1999)
Despite such advances in screening and treatments, there continues to be 
significant mortality from each of these diseases with the result than cancer 
remains one o f the most common causes o f death in the developed world. For 
cervical cancer there are non-randomised data which show a significant 
reduction in cancer specific mortality where screening has been introduced 
(Duggan, 2012; Kitchener et al, 2010). For other types o f solid tumours such
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as gastric and ovarian there is less than level 1 evidence and ongoing 
randomized trials (Menon et al, 2008; Partridge et al, 2009). For other solid 
tumour types such as pancreatic, oesophageal and hepatocellular cancer there 
are no screening tests which thus far hold much promise and systemic 
therapies are also o f limited effectiveness.
Diagnosing cancers with a blood test would seem a simple and relatively easy 
approach. However for a blood test to be useful in the diagnosis o f primary 
cancers, it needs to be sensitive enough to detect early disease and specific 
enough to be effective in a screening context. Majority o f blood tests for 
cancer markers presently available look into level o f cancer-associated 
antigens. Examples o f classical ‘tumour markers’ would be CEA for colorectal 
cancer, CA15.3 for breast cancer and CA125 for ovarian cancer, all o f  which 
reflect a dynamic overview o f disease burden (tumour load) in the individual. 
Thus these markers has been traditionally used in diagnosing recurrences and 
monitoring treatment o f metastatic cancers, and found to be not particularly 
useful in diagnosising early cancers. As methods o f detection o f antigens has 
become more sensitive many researchers have focussed on proteomics using 
chromatography looking for abnormal patterns associated with different types 
o f cancer. Thus far these techniques have not been proven effective either in 
detecting early disease or specific enough for screening(Liu et al, 2012; Ma et 
al, 2012).
A new approach in improving the early diagnosis o f  certain cancers especially 
lung cancers is the use o f real time PCR. miRNA expression is involved in
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cancer development and progression as a tumour suppressor or oncogene, and 
its aberrant expression has been used as a biomarker for the diagnosis o f lung 
cancer. Bianchi F and colleagues from Milan have developed a multivariate 
risk-predictor algorithm based on the weighted linear combination o f the 34- 
miRNA expression levels and they predicted an overall accuracy o f 80% 
(sensitivity 71%, specificity 90%; AUC 0.89) in a group o f asymptomatic lung 
cancer patients detected using LD-CT(Bianchi et al, 2012). Studies from other 
centers on miRNA on lung cancer patients has published similar accuracy in 
the diagnosis o f lung cancer patients (Hennessey et al, 2012). Similar research 
has been published in other forms of cancer (Kang et al, 2012). Stathminl is a 
candidate oncoprotein and prognostic marker in several cancers and the above 
paper supports its oncologic role in gastric cancer.
Another field which has recently attracted significant attention with a large 
number o f publications has been the presence o f humoral immune response to 
cancer (amplified signal) produced in response to the cancer derived antigens. 
These ‘autoantibodies’ to cancer modified antigens are present in measureable 
amounts not only in detectable early stage cancer but have even been reported 
to be measureable in the peripheral blood months to years before cancers are 
diagnosed(Li et al, 2005; Robertson JFR, 2005a; Robertson JFR, 2005b).
The measurement o f  autoantibodies in the peripheral blood as a means o f 
diagnosising early stage cancer has been reported previously from our 
institute, including lung and breast cancers(Chapman et al, 2007; Chapman et 
al, 2008) and has eventually led to the establishment by the University o f 
Nottingham of a spinout company (Oncimmune Ltd) whose aim has been to
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identify raised levels o f such antibodies in individuals with a cancer and 
provide clinical blood tests as an aid to diagnosis that can be used alongside 
current imaging techniques. The basis for the research programme has been 
that in defined high risk populations raised levels o f autoantibodies could be 
identified in the preclinical and early stage disease and that linked to modem 
imaging technologies this would result in detection o f the cancer earlier, 
leading to not only improved survival but also reduction in cancer specific 
mortality. These studies have compared the autoantibody signal in sera derived 
from both cancer and normal individuals (Chapman et al, 2007; Chapman et 
al, 2008) . Screening is usually thought to be appropriate only for high risk 
groups and so these published studies34 35 like most similar studies were 
performed in cancer patients and high risk groups o f individuals. As such, 
knowledge o f the tumour associated antibody responses in the normal 
population is largely unknown. The EarlyCDT-Lung™ test (Oncimmune Ltd) 
measures autoantibodies (AABs) to six cancer-associated antigens (p53, NY- 
ESO-1, CAGE, GBU4-5, Annexinl, and SOX2) and has been reported to 
identify up to 40% o f lung cancers regardless o f grade or stage o f the disease. 
These 6 antigens are described in more detail in the following sections but in 
brief they include well-recognised cancer-associated antigens like the p53 
suppressor oncogene which is mutated in large number o f cancers (Linzer & 
Levine, 1979; Soussi, 2000b) and also two previously described cancer testes 
antigens, NY-ESO-1 (Chen et al, 1997a) and CAGE (Chapman et al, 2008). 
GBU4-5 is a recently identified protein and like CAGE it encodes a DEAD- 
box domain and has been described to produce antibody response in lung 
cancers (Cho et al, 2003a). Annexin 1 belong to a family o f  calcium2+ and
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phospholipids-binding, membrane associate proteins with varied expression in 
different cancers and antibody response to these antigens has been recorded in 
significant proportion o f lung cancers (Ahn et al, 1997; Yeatman et al, 1993). 
Finally, SOX2 is a high mobility group box transcription factor involved in the 
maintenance o f pluri-potency and self-renewal in embryonic stem cells and 
has been identified in the serum in high frequency in patients with squamous 
cell and small cell lung cancers (Bass et al, 2009; Titulaer et al, 2009).
To our knowledge the autoantibody response to cancer related antigens has not 
been assessed in a large group o f normal subjects with no personal history o f 
cancer. We believe this study is the first o f its kind looking into the spectrum 
o f autoantibody response in a normal population, with or without a family 
history. In addition the study will also look at whether benign autoimmune 
disease might interfere with the autoantibody response to cancer modified 
antigens by such individuals. We hypothesise that autoantibody response to 
cancer associated antigens may alter with demographics and the objective of 
our study to investigate the influence o f age, gender, smoking and benign 
autoimmune diseases on antibody response to the cancer related antigens 
described above, in a large cohort o f subjects with no previous personal history 
o f cancer.
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1.2 Review of literature
1.2.1 Cancer statistics
Cancer is one o f the leading causes o f death, and in United Kingdom it 
accounts for one in four (27%) o f all deaths(2006a; 2006b; statistics, 2006) . 
On an average around 293,000 new cancers are diagnosed each year(Aug 
2009) with overall 1:1 ratio in males to females. In males the most common 
cancers are lung, prostate and colorectal and in females they are lung, breast 
and colorectal. The incidence o f lung cancers are 68% higher in males than in 
females (62 and 37 per 100,000 respectively) and the incidence o f colorectal 
cancers are 58% higher in males (55 and 35 per 100,000 for males and females 
respectively). Breast cancer and prostate cancer represent the highest incidence 
among cancers in females and males respectively, and incidence o f breast 
cancer (122 per 100,000) is 24% higher than the incidence o f prostate cancer 
(98 per 100,000)(Aug 2009).
On average there are approximately 155,000 cancer deaths each year. The age 
standardized mortality rate for men and women were 211 and 153 per 100,000 
respectively. The three most common cancers for both sexes was also the most 
common cause o f death from cancer. In females the mortality from lung cancer 
was only slightly higher than breast cancer (28 and 31 per 100,000 
respectively) although the incidence o f lung cancer is much lower- a reflection 
o f the much higher mortality rate for lung cancer compared to breast cancer. In 
men the mortality from lung cancer was twice that o f prostate cancer (53 and 
26 per 100,000 respectively), again a reflection o f the greater mortality rate 
from lung cancer. The mortality from lung cancer was 75% higher in males
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than females. The mortality rate for colorectal cancer was 59% higher in males 
than females (20 and 13 per 00,000 for males and females respectively). In the 
UK, overall Scotland had higher mortality rates for both sexes, about 16% 
higher than those for the UK as a whole, and overall cancer incidence rates 
were 8% higher(Aug 2009).
Although cancer deaths are more common in the elderly, cancer causes a 
greater proportion o f deaths in the young and relatively greater years o f life 
lost to cancer (eg breast cancer)(Boyle et al, 1995). Cancer is responsible for a 
third o f  all deaths under the age of 65 years compared to a quarter o f all deaths 
in over 65’s(2006a; 2006b; statistics, 2006).
1.2.2 Screening
Screening is looking for cancer in people who have no symptoms or looking 
for conditions which could lead to cancer. It may not be useful in all cancers, 
and to be effective it should have a long occult growth period where they can 
be detected before the cancer has spread leading to treatment that could 
improve survival. Thus not all screening tests are useful, and some have risks 
associated with it ie. Flexible sigmoidoscopy or colonoscopy can injure the 
bowel wall and can also cause bleeding. False positive results may lead to 
anxiety and further tests which may themselves lead to complications. False 
negative results may lead to a false sense o f being normal even when presented 
with symptoms, leading to delay in seeking medical care.
Between 1977 and 2006 the European age-standardised mortality rates for all 
malignant neoplasms fell by 17% from 215.9 to 178.6 per 100, 000 
population(2006a; 2006b; statistics, 2006). Along with the recent availability
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o f better cancer treatment, early detection through screening has an important 
part in more recent improved survival(Henschke et al, 2006; Labrie et al, 
1999; Otto et al, 2003; Tabar et al, 2003). However available screening 
modalities for cancer have limitations and an ideal screening test should have 
high sensitivity, specificity, should be reproducible, cheap, non-invasive and 
acceptable to patients.
1.2.2.1 Lung cancer screening
Lung cancer is the commonest cancer worldwide representing approximately 
12% o f all new cancers(Youlden et al, 2008). It is also most common type o f 
cancer in males and remains the most common cause o f cancer related 
mortality in both sexes. The majority o f patients worldwide still present with 
advanced inoperable stage(Parkin et al, 2005; Youlden et al, 2008). Overall 5- 
year survival for lung cancer in men and women are in the range o f 13 and 17 
percent respectively and this poor outcome is almost uniformly due to late 
stage o f disease at diagnosis(Ries LAG). If  lung cancers are diagnosed early, 
the 5-year survival rate for UICC stages I is reported to be over 70%(Flehinger 
et al, 1992). Cancers which are diagnosed very early, for example those 
involving only the very few layers o f cells in a localized area, the survival is 
even better and it may approach 80%. The fact that this is not simply due to 
lead time bias was shown in the recent publication o f the NLST study which 
reported that screening with three annual computerised tomography (CT) scans 
reduced lung cancer mortality by 20%(Aberle et al, 2011)
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Previous non-randomised trials with low radiation dose CT had shown CT had 
a high sensitivity for small non-calcified pulmonary nodules, the most 
common manifestation o f early lung cancer. Screening of high risk group 
using low dose CT has shown a prevalence rate ranging from 0.4% to 2.7% 
and incidence rate (results o f repeat screening) ranging from 0.3% to 1.2%. In 
a study by MacRedmond et al looking into 449 high risk subjects undergoing 
low dose CT, the prevalence rate was 0.4% and incidence rate o f 0.7% at 2 
years(MacRedmond et al, 2006). Overall, 2 o f the 9 lung cancers diagnosed 
were stage 1 non small cell lung cancer. In the Early Lung Cancer Action 
Project (ELCAP), Henschke et al reported a prevalence o f 2.7% (27/1000) and 
incidence o f 0.7% (6/841)(Henschke et al, 2001). Eighty one percent (27/33) 
o f the cancers diagnosed were o f stage 1 disease. New York Early Lung 
Cancer Action Project (NY-ELCAP) looking into 6295 high risk subjects 
undergoing CT screening reported a prevalence o f 1.6% (101/6295) and 
incidence o f 0.3% (20/6014)(New York Early Lung Cancer Action Project, 
2007). In another study involving 817 high risk subjects undergoing low dose 
CT screening reported by Diederich and colleagues, the prevalence rate was 
1.5%(12/817) and incidence rate o f 1.2% (10/792)(Diederich et al, 2004). 
Seven out o f the 12 patients (58%) diagnosed with lung cancer in the 
prevalence group were stage 1 disease and 7/10 (70%) patients in the 
incidence group had stage 1 disease. In a prospective cohort study by Stephen 
and colleagues looking into 1520 high risk individuals aged 50 years or older 
the prevalence rate o f lung cancer was reported to be 1.6% (25/1520) and the 
incidence rate was 0.3% (3/1000)(Swensen et al, 2002). Pastorino and 
colleagues reported the use spiral CT and positron emission tomography in
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high risk group o f 1035 subjects aged 50 years or over who had smoked for 20 
pack-years or more(Pastorino et al, 2003). All patients had annual CT with or 
without PET for 5 years. By year two, 22 cases o f lung cancer were diagnosed 
(11 at baseline, 11 at year 2). Complete resection o f the tumour was possible in 
21(95%) o f lung cancer patients and 17 (77%) of them were o f stage 1 disease 
at pathological diagnosis. It is important to note that true potential o f a 
screening test is not reflected by the prevalence results, but by incidence 
results (results at repeat screening) which should also give information o f 
screening intervals.
In a recent RCT by van Klaveren and colleagues, in a large group o f over 
7500 subjects with high risk o f lung cancer undergoing CT screening in year 1, 
2 and 4, following the first and second rounds o f screening, 2.6 and 1.8 of the 
participants respectively had positive test result. The sensitivity o f the test was 
94.5% (95 Cl; 86.5 to 98) and the negative predictive value was 99.9% (95 Cl; 
99.9 to 100). Twenty lung cancers were detected in 7361 subjects with a 
negative screening result in round one after 2 years o f follow-up(van Klaveren 
et al, 2009).
Screening high risk populations for early-stage lung cancer using CT scans has 
therefore been shown to reduce lung cancer mortality. Other potential 
screening techniques include serum analysis for tumour associated antibodies, 
advanced sputum analysis in combination with autofluoresent bronchoscopy, 
and assessment o f molecular markers in sputum. None of these techniques 
have thus far been reported in randomized clinical trials.
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1.2.2.2 Breast cancer screening
The breast cancer mortality rate in UK has been falling since the late 
1980’s(statistics, 2006) and is one area where screening has been extensively 
evaluated and reported to be successful. Screening trials have taught us that 
timing o f treatment in relation to natural history o f the disease is probably 
more important in the final outcome rather than the choice o f treatment(Tabar 
& Dean, 2008). With the introduction o f mammographic breast screening there 
has been a shift from primary palpable more advanced cancer to non-palpable 
good prognostic pre invasive and invasive cancers which may not require the 
adjuvant treatment and thus avoiding its toxic effects. On the other hand some 
experts believe there is a significant over-diagnosis rate(Moynihan et al, 2012) 
and a recent review o f analysis o f data from Norway estimate that 15% to 25% 
of breast cancers identified on mammography would never have been 
clinically significant in a women’s lifetime.(Elmore & Fletcher, 2012)
One o f the early RCT o f mammographic screening began in Sweden in 1977 
in the counties o f Kopparberg and Ostergotland. Randomisation into the trial 
took place between 1977 and 1980 between the ages o f  40 to 74 years. Invited 
to screening group comprised 77092 women and the not invited group 
comprised o f 56000 women(Tabar et al, 2002). After an approximately mean 
follow-up o f 10 years, there was a 31% reduction in breast cancer mortality in 
the invited group (RR 0.69, 95% Cl 0.58-0.80; p<0.001). These results have 
been consistent with the results in other mammographic screening 
trials(Nystrom et al, 2002). In England and Wales, based on recommendations 
o f the Forrest committee, the breast cancer screening program was introduced
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in 1988 (Quinn & Allen, 1995). By 1994, there was a reduction o f 12% 
mortality compared to prescreening rates in the late 1980s in patients between 
55-69 years o f age. While the widespread use o f adjuvant tamoxifen could 
account in part for these improved survival results in the later decade, breast 
cancer screening using mammograms has thought to have played a significant 
role in reducing mortality(Quinn & Allen, 1995).
In United States, the American College o f Surgeons recommends annual 
mammographic screening beginning at the age o f 40 years. In the UK 
mammographic screening under the National Health Service (NHS) for all 
women commences at 47 years o f age. Screening women younger than 47 
years on the NHS is only allowed if  the patient can be shown to be above 
population risk either through family history or having a genetic mutation, 
such as BRCA 1 or 2 or p53, known to be associated with increased risk o f 
developing breast cancer. A meta-analysis o f previous mammographic 
screening trials has reported a 15% reduction in breast cancer mortality in 
women aged 40-49 years at entry who were invited to screening(Miller et al, 
1992). However most o f the results included in this meta-analysis were from 
subgroup analysis o f larger trials and there has been a view expressed that a 
significant proportion o f patients in these trials reached 50 years soon after 
entry into the trial and the mortality benefit could have been due to 
mammograms performed after the age o f 50 years(Smith et al, 2004). To 
overcome this issue the ‘Age Trial’ was designed and run in the United 
Kingdom(Moss et al, 2006). In a recent report of this trial, following 10.7 
year mean follow-up o f 16,0921 women aged 39-41 years randomly assigned 
on a 1:2 ratio to an intervention group (annual screening mammogragms from
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entry to age 48 years) or control group showed a reduction in breast cancer 
mortality in the intervention group relative to the control group of 17% which 
was not statistically significant ( relative risk 0.83, 95% Cl 0.66-1.04;P=0.11). 
There is relatively little follow-up beyond 10 years and results o f  longer 
follow-up are awaited. Comparatively low mortality benefit in younger 
patients could be attributed to low sensitivity o f mammograms in this group. 
The sensitivity o f mammograms is shown to be inversely proportional to the 
density o f  the breast. In women under the age o f 50 years almost half have 
dense breast tissue and approximately one third o f the women over the age of 
50 have still dense breast(Stomper et al, 1996). Apart from that there appears 
to be a shift o f balance towards number induced by screening compared to the 
breast cancer deaths prevented by screening in patients using mammograms 
under the age o f 50 years(Beemsterboer et al, 1998). Similar trend has been 
noted in BRCA mutation careers(Berrington de Gonzalez et al, 2009).
One of the well documented risk factors for breast cancer is family history, 
and genetic predisposition which accounts for 5-10 % of all breast 
cancers(Easton et al, 1995). The closer the relative and the younger the 
relative at first diagnosis, then the greater is the risk o f breast cancer. With no 
first degree relative with breast cancer, the life time risk o f breast cancer (up to 
80 years) is 7.8% (approximately 1 in 13)(Collaborative Group on Hormonal 
Factors in Breast, 2001). With one first degree relative the risk becomes 
almost twice (1 in 7.5) and with 2 first degree relatives the risk becomes 
almost 3 times (more than 1 in 5). While the optimal time to start screening 
women with a family history remains to be established some experts have 
proposed that it is advisable to start screening approximately 10 years before
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the age o f diagnosis o f  first degree relative(Dershaw, 2000) with a lower limit 
o f 30 years based on family history alone since the incidence o f breast cancer 
in this group is very small before this age. However women who are known or 
suspected to carry BRCA1 and BRCA2 mutations are at a particularly high 
risk o f breast cancer, especially at earlier age in BRCA1 carriers. The 
incidence o f breast cancer among BRCA1 carriers in their 20s exceeds those 
o f women with no family history in their 40s and thus it may be reasonable to 
start screening in this group even in their 20s(Berg, 2009).
Because o f low sensitivity o f mammograms in younger age group, it has been 
combined with other screening tools like MRI or ultrasound. In high risk 
women the combined sensitivity o f mammogram and MRI has been reported 
to be 92.7% compared to 52% with USS and mammogram(Kuhl et al, 2005). 
However MRI is less well tolerated and expensive compared to 
ultrasound(Kuhl et al, 2005). Another disadvantage is that, although MRI is 
not affected by density o f the breast as opposed to mammograms, its 
comparatively low specificity leads to potentially unnecessary biopsies and 
anxiety.
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1.2.3 Genetic changes in cancer
There has been an explosion in the knowledge about molecular basis o f cancer 
in the last 30 years and it is now recognized that genetic instability (mutation 
or altered expression o f genes) is thought to be the driving force involved in 
the initiation and progression of cancer. (Shen, 2011). In non cancerous 
somatic cells, the duplicated genome is evenly divided into the two daughter 
cells, thus ensuring that they receive the same genetic material as their parent 
cell. These cell divisions are tightly regulated and failure o f this regulatory 
process or errors during this process will result in various forms o f genome 
alteration in daughter cells. Accumulation o f these alterations results in dys- 
regulation o f cell division eventually leading to cancer. In cancer cells, 
additional genetic alteration can result in sub-population o f cells with more 
aggressive properties than others and thus accumulation o f genetic alterations 
is not only a hallmark but also a driving force in tumorigenesis.
In addition to this, environmental factors and epigenetic changes (changes in 
the gene caused by mechanisms other than changes in the underlying DNA 
sequence) play an important role in the development o f cancer.
Three classes o f genes may play a role in cancer initiation -  Oncogenes, 
tumour suppressor genes and genes involved in DNA repair (Caretaker genes). 
Genetic alterations (mutation, amplification and deletion, translocation) 
involving the three classes o f genes leads to derangement o f mechanisms 
involved in normal cell growth and differentiation and ultimately culminate in 
the six biological endpoints which characterize malignant growth i.e. evasion 
o f apoptosis, insensitivity to anti-growth signals, sustained angiogenesis, 
limitless replicative potential, self-sufficiency in growth signals and tissue
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invasion and metastasis(Hanahan & Weinberg, 2000). Genetic instability in 
cancers is thought to occur at two distinct levels(Lengauer et al, 1998; Michor 
et al, 2005). In a small group of cancers instability is observed at the 
nucleotide level resulting in a base substitution or deletion or insertions o f a 
few nucleotides. In most o f the cancers the genetic instability is seen at the 
chromosome level resulting in losses or gains o f a whole chromosome or large 
portions o f it. The consequence is an imbalance o f chromosome number 
(aneuploidy) and an increased rate o f loss o f heterozygosity (loss o f normal 
function o f one allele o f a gene in which the other allele was already 
inactivated) which in turn accelerates the inactivation o f tumour suppressor 
genes.
Oncogenes are mutated forms o f normal genes called pro-oncogenes which 
control normal cell division and become permanently activated or tuned on 
with mutation leading to abnormal cell division and cancer. Only one o f the 
alleles o f the proto-oncogene needs to be overactive in order to have an 
oncogenic effect. A classical example is the Philadelphia chromosome in 
chronic myeloid leukemia.
Tumour suppressor genes encodes proteins that normally slow down cell 
division, repair DNA mistakes and trigger apoptosis, and their inactivation 
though genetic alteration can lead to cancer. Although it was initially thought 
that both alleles o f  the gene needs to be inactivated in order to render it 
inactive, some tumour suppressor genes needs only one allele to be mutated to 
produce an oncogenic effect(Knudson, 1971). The best known tumour 
suppressor gene is P53 gene which is the most frequently inactivated gene in 
human cancers and is described in more detail later. Another example is the
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familial breast cancer associated genes (BRCA 1 and BRCA 2 gene) which act 
as adaptors that convey the damage signal to various mechanisms that induce 
repairs, arrest damage or promote apoptosis(Shiloh, 2003; Venkitaraman, 
2004). Caretaker genes also known as stability genes are a class o f tumour 
suppressor genes involved in recognizing and repairing DNA 
damages(Vogelstein & Kinzler, 2004).
It is estimated that the human genome has twenty to twenty-five thousand 
genes and at present more than 300 are known to play a role in the 
development o f cancer(Lander et al, 2001). A study o f breast and colorectal 
cancer cell lines has shown that these cancer cells may have an average o f 90 
mutant genes (Sjoblom et al, 2006). However there is also an argument that 
the large scale genetic instability seen in cancer could be a consequence o f 
neoplastic process rather than its cause itself and only a few mutations are 
actually responsible for the development o f  cancer(Fearon & Vogelstein, 
1990). The other insignificant mutations are called bystander(Ilyas et al, 1999) 
or passenger mutations(Sjoblom et al, 2006).
Development o f cancer is thought to be a multi-step process requiring 
accumulation o f mutation in a number o f genes. In sporadic cases the initial 
genetic alteration occurs in a single cell and if  this is not repaired it is passed 
on to the daughter cell during cell division. If one o f the daughter cells 
acquires another genetic alteration it passes on this as well as the original 
alteration to its daughter cells. This process eventually leads to population o f 
increasingly abnormal cells and subsequent development o f cancer.
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There is some dispute about the cell type involved in carcinogenesis. 
Increasingly scientists believe that cancer arise from stem cells (tumour 
initiating cells)(Bjerkvig et al, 2005; Jordan et al, 2006). Evidence o f cancer 
stem cells was first reported for leukaemia and myeloma where it was found 
that a small subset o f cancer cells was capable o f extensive proliferation and to 
form new tumours(Bruce & Van Der Gaag, 1963; Park et al, 1971; Wodinsky 
& Kensler, 1966). Similar cells have been identified in breast and brain 
cancers (Al-Hajj et al, 2003; Singh et al, 2003). They are thought to occur as a 
result o f deranged cell division or cell fusion events. It has been defined as a 
cancer cell that has the ability to self-renew giving rise to another malignant 
stem cell as well as a cell that will give rise to the phenotypically diverse 
cancer cells (Houghton et al, 2007; Sell, 2004). In this model there could be 
disruption o f genes involved in the regulation o f stem-cell self renewal. It is 
thought that the environment or the “niche” surrounding the stem cells 
provides signals necessary for the stem cells to continue to self-renew and that 
upon exit from this niche the stem cells begin to undergo 
differentiation(Spradling et al, 2001).
Majority o f the cancers are sporadic and caused by progressive accumulation 
o f genetic mutation and/or epigenic changes during person’s lifetime. They are 
called somatic mutations and are not heritable. In contrast, some individuals 
are bom with increased susceptibility to cancer through inheritance o f single 
genetic mutation and this can be passed on from generation to generation. It is 
estimated that approximately 1% o f cancers are caused by these high risk 
mutations which generally effect tumour suppressor genes(Aamio et al, 1999). 
Individuals with high risk mutations have a one in two chance o f passing the
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mutated gene to their offspring and are copied to every cell in the child’s body. 
Unless both parents are carriers, the child would inherit one mutated and one 
normal allele. Although both alleles need to be mutated in order to lose the 
function o f the gene and develop cancer, these individuals only need one more 
mutation to be susceptible and are therefore high risk group. In this group 
cancers arise at a younger age than the general population.
Tendency o f cancers to aggregate in families cannot be wholly explained by 
the rare inherited high risk mutation. A substantial proportion o f such cancers 
are thought to be due to combined effects o f multiple common gene variants 
known as polymorphisms, each o f which is associated with an increased risk 
o f cancer(Peto & Houlston, 2001). Mutation in BRCA 1 and BRCA 2 do not 
account for all cases o f familial breast cancers. In fact most cases are due to 
families carrying one or more genetic polymorphisms. It has been found that 
inheriting particular polymorphism called 1 lOOdelC a variant of CHEK2 gene 
would double a woman’s risk o f breast cancer and increases the risk o f cancer 
in males by ten-fold (Meijers-Heijboer et al, 2002). Irrespective o f family 
history, an individual’s risk o f developing cancer is likely to be influenced by 
their genetic make-up, most commonly by the combination o f polymorphisms 
they have inherited. The interaction o f these gene variants with each other and 
with environmental risk factors is likely to determine overall cancer risk. HRT 
and oral contraceptives are some o f the common environmental risk factors 
implicated in breast cancer and will be discussed in detail later (1997; Beral, 
2003; Rossouw et al, 2002).
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1.2.4 Stages of cancer development
Many forms o f cancers are thought to arise from premalignant lesions which 
subsequently progress to invasive cancer. Well known examples o f this 
process are colorectal cancer, breast cancer, bladder cancer, prostate cancer 
and cervical cancer
1.2.4.1 Adenoma carcinoma sequence (polyp-cancer sequence) 
in colorectal cancer
It has been widely accepted that adenoma-carcinoma sequence represents the 
process by which most o f the colorectal cancers, if  not all develop. There is 
substantial epidemiological, clinico-pathological and genetic evidence behind 
this theory. Prevalence o f both colonic polyps and colorectal cancers increase 
with age, but the prevalence o f adenomas peak 5 years earlier than that of 
colorectal cancers (Muto et al, 1975). Prior to the era o f colonoscopic 
polypectomy several studies examined the progression o f polyps left in-situ 
and colorectal cancer developing at the site o f index polyp was observed 
(Bersentes et al, 1997; Hoff et al, 1986; Knoemschild, 1963; Stryker et al, 
1987). There have also been reports o f  foci o f malignancy within 
polyps(Colacchio et al, 1981; Shinya & Wolff, 1979)and conversely, remnants 
o f adenomatous tissue within invasive colorectal cancers (Muto et al, 1975). 
Adenomas are also found to coexist with cancers in approximately 30% of 
cases at endoscopy or in the specimen (Arenas et al, 1997; Chu et al, 1986; 
Langevin Sc Nivatvongs, 1984). It has also been noted that adenomas are 
encountered more frequently in patients with synchronous tumours than those 
with single primary cancer (Langevin & Nivatvongs, 1984). Similarly those
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patients with colorectal cancer and simultaneous adenomas have been shown 
to have a higher risk o f synchronous and metachronous tumours (Chu et al, 
1986). The anatomical distribution o f adenomas and carcinomas are similar 
and both occur more frequently distal to the splenic flexure (Chu et al, 1986; 
O'Brien et al, 1990). Finally polypectomy reduces the long term risk of 
colorectal cancer (Atkin et al, 1992; Hoff et al, 1996; Muller & Sonnenberg, 
1995; Selby et al, 1992; Winawer et al, 1993) and randomised controlled trials 
have shown that screening reduces the incidence o f colorectal cancer (Mandel 
et al, 2000).
Apart from the above epidemiological and clinico-pathological evidence, the 
genetic evidence behind this theory is also compelling. These genetic 
alterations often occur in a sequence that parallels the clinical progression of 
the tumour. However it is the total accumulation o f changes rather than the 
order is the key factor in the progression (Fearon & Vogelstein, 1990; 
Vogelstein et al, 1988). Mutation involving the adenomatous polyposis coli 
(APC) tumour suppressor gene occurs early in the adenoma-carcinoma 
sequence and is located on chromosome 5q21 (Bodmer et al, 1987; Groden et 
al, 1991). Mutated APC has been demonstrated in adenomas as small as 0.5 
cm(Powell et al, 1992). APC mutations or allelic losses o f 5q are observed in 
40-80% o f colorectal cancers and found in similar frequency in adenomas (Jen 
et al, 1994; Miyaki et al, 1994; Miyoshi et al, 1992; Powell et al, 1992). The 
allelic loss or loss o f heterozygosity has been shown to increase in frequency 
from early adenomas through to invasive carcinomas (Miyaki et al, 1994). 
Similarly K-ras genetic alteration occurs early in the adenoma-carcinoma
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sequence. 35-42% of colorectal cancers have this mutation (Vogelstein et al, 
1988) and similar frequencies are observed in large adenomas (Andreyev et al, 
1998; Bos et al, 1987; Forrester et al, 1987; Hardingham et al, 1998).
P53 is the gene most frequently altered in human cancers and is located in the 
short arm o f chromosome 17(Caron de Fromentel & Soussi, 1992). It is 
labelled as the guardian o f the genome because o f its ability to block cell 
proliferation in the presence o f DNA damage, to stimulate DNA repair and to 
promote apoptotic cell death if  the repair is insufficient (Lane, 1992). 
Alteration in p53 or 17p allelic loss has been reported in 4-26% of adenomas 
(Darmon et al, 1994; De Benedetti et al, 1993; Kaklamanis et al, 1993; Ohue 
et al, 1994; Scott et al, 1993; Vogelstein et al, 1988; Yamaguchi et al, 1994), 
approximately 50% of invasive foci within adenomas (Ohue et al, 1994; 
Yamaguchi et al, 1994) and 50-75% adenocarcinomas (Boland et al, 1995; 
Darmon et al, 1994; Hardingham et al, 1998; Kaklamanis et al, 1993; Kaserer 
et al, 2000; Vogelstein et al, 1988). These observations have led to the belief 
that loss o f p53 function is associated with the transition from adenoma to 
carcinoma.
1.2.4.2 Premalignant to malignant change in breast cancer
It is widely believed that many breast cancers originate as a premalignant
stage o f atypical ductal hyperplasia which progress to DCIS and culminates in 
invasive breast cancers. A proportion o f DCIS if  not treated progress to 
invasive disease. From autopsy studies it is estimated that approximately one 
third o f the DCIS progress to invasive cancer (Nielsen et al, 1984). The 
median age o f patients with DCIS is reported to be 45-65 which is not
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different from that reported from patients with invasive cancer and there is a 
trend towards lower median age in patients with DCIS detected by screening 
mammography (Sakorafas & Tsiotou, 2000). The family history o f breast 
cancer in first degree relatives o f DCIS patients is similar to that reported from 
invasive malignancy (10-35%)(Robinson KE, 1999). Another factor which 
supports this theory is that a significant proportion o f breast cancers (%) are 
found to have associated DCIS on histopathology. However, the most 
convincing evidence o f DCIS being a forerunner for invasive cancer comes 
from studies in which patients with DCIS were initially misdiagnosed with 
benign lesions and were subsequently identified as DCIS (Betsill et al, 1978; 
Eusebi et al, 1994; Farrow, 1970; Page et al, 1995; Page et al, 1982; Rosen et 
al, 1980). Eventually invasive recurrence developed in a large percentage of 
women (15-75%). In patients with DCIS the risk o f development of 
subsequent invasive cancer is estimated to be approximately 11 times higher 
than the normal population. Another convincing piece of evidence is that 
among patients with DCIS undergoing surgery alone, approximately 50% of 
the recurrences following surgery are invasive cancers. These recurrences are 
significantly higher in those patients undergoing wide local excision alone 
compared to mastectomy.
1.2.5 Risk factors for cancer
1.2.5.1 Age at diagnosis
Cancer is predominantly a disease o f the elderly with approximately 75% of 
cases diagnosed in people aged 60 or over and less than 1% o f cases occur in
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children (Office o f national statistics, 2009; Online, 2009). The common solid 
tumours including breast cancer, lung cancer, bowel and colorectal cancers are 
all increasingly commoner in the elderly.
Age is one o f the most important risk factors for breast cancer. Breast cancer is 
uncommon before the age o f 30 years but rises rapidly until 40 years and there 
after continues to increase in prevalence at a slower rate (McKinnell RG, 
199S). It accounts for nearly half of all cancer diagnosed in UK women aged 
40-59 years (Office o f national statistics, 2009; Online, 2009). Prior to 40 
years of age the likelihood o f developing breast cancer is 1 in 200 and the 
likelihood increases from 1 in 15 between the ages o f 60 to 79 years 
(McKinnell RG, 1998).
Although the age-adjusted incidence o f breast cancer is increasing, the 
morality has fallen recently. Breast cancer in women is second only to lung 
cancer as the leading cause o f death by cancer in spite being 2-3 times more 
women being affected with breast cancer (McKinnell RG, 1998). Breast 
cancer is the leading cause o f cancer death in women 15-54 years. Lung cancer 
has over taken as the primary cancer killer from the age o f 55 onwards.
1.2.5.2 Heredity and cancer
Heredity is one o f the most important risk factors for breast cancer. A women 
with a first degree relative with breast cancer before the age o f 45 years has a 
3.85 times greater risk than women o f general population (Houlston et al, 
1992). Many genes are known to be involved in the development o f breast 
cancer. Deleterious mutation in BRCA l(Futreal et al, 1994; Miki et al, 1994)
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and BRCA 2(Wooster et al, 1994) are well known for their increased lifetime 
risk o f breast and ovarian cancer. Men are at an increased risk o f breast 
(primarily BRCA 2) and prostate cancer. The prevalence o f BRCA 1 mutation 
is estimated to be 1/800 in the general population. Lifetime risk o f  breast 
cancer in women with BRCA 1 and BRCA 2 mutations varies from 56% to as 
high as 80-85% (Easton et al, 1993; Easton et al, 1995; Struewing et al, 1997). 
The probability o f detecting a deleterious mutation in BRCA 1 or BRCA 2 is 
higher when there is a family history o f both breast and ovarian cancer 
compared with women with breast or ovarian cancer alone(Couch et al, 1997). 
BRCA 1 mutations are seen in 75% of families with both breast and ovarian 
cancer in a single individual.
Age o f onset o f breast cancer is also important as younger ages o f onset 
(diagnosed at the ages o f 40 years or younger) o f breast cancer are associated 
with a deleterious mutation, especially a mutation in BRCA 1 (Berry et al, 
1997). Women with inherited susceptibility generally have breast cancer at a 
younger age. As cancer evolves from a multistep process with several 
mutations rather than one, only fewer genetic changes are required in those 
patients with inherited genetic change to result in malignancy. Thus the 
inherited form is likely to occur earlier. In women with sporadic breast cancer 
the incidence peaks one or two decades later than those who have detectable 
BRCA 1 mutations.
Approximately 15-20 % o f individuals referred for testing are found to have 
mutation involving either BRCA1 or BRCA 2 gene. Among men with breast 
cancer, about 25% carry mutations and o f these more than one third occur in
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BRCA1. BRCA 1 mutations are found to be three times more prevalent than 
BRCA 2 mutations in families with male breast cancer.
The average age o f breast cancer diagnosis is significantly younger in the 
families with BRCA1 (41.4 years) or BRCA2 mutations (40.1 years) than in 
families without detectable mutations (50.1 years) (P < .0001) (Shih et al, 
2002). Probands with BRCA1 and BRCA2 mutations were diagnosed with 
breast cancer at an average age o f 37.6 and 32.1 years, respectively (P = .028). 
Women who carry an abnormal ataxia telangiectasia (AT) gene are associated 
with increased risk o f breast cancer (Athma et al, 1996; FitzGerald et al, 
1997).
Around 75% of colorectal cancers occur sporadically in people over the age of 
50 years. Bowel cancers occur as a result o f multiple mutations within a cell in 
the bowel lining allowing it to escape the normal growth control mechanisms. 
The step wise accumulation o f mutations drives the histological transition 
from normal tissue to adenoma to carcinoma(Feamhead et al, 2002). Most 
common genetic alterations in sporadic bowel cancers are activating mutations 
in the oncogene KRAS and mutation or loss o f the tumour suppressor genes 
APC, SMAD4 and TP53. Evidence suggest that occurrence o f APC mutations 
represents the earliest step in colorectal carcinogenesis and both copies o f the 
APC genes are inactivated in 80 % o f sporadic cases (Miyoshi et al, 1992; 
Powell et al, 1992).
Familial adenomatous polyposis (FAP) accounts for only 1% of colorectal 
cancers. However, they have a 100% risk o f bowel cancer by the age o f 40
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years. The gene o f FAP is the APC tumour suppressor gene on chromosome 
5q21 (Bodmer et al, 1987). Hereditary non-polyposis colorectal cancer 
(HNPCC) or Lynch syndrome, is responsible for another 2-5% of colorectal 
cancers. It is a result o f a DNA mismatch repair(MMR) gene (Liu et al, 1996). 
It is often associated with other cancers including endometrial, ovarian, 
stomach, pancreatico-biliary and urinary tract. Studies on colorectal cancers 
below 30 years o f age show that approximately 41% are carriers o f MMR gene 
mutations(Farrington et al, 1998). The risk o f people with these mutation to 
develop colorectal cancer by the age o f 70 years is 91%(Dunlop et al, 1997). 
Apart from FAP and HNPCC, hereditary factors account for another 20% of 
colorectal cancers and a national collaborative study is looking into other 
genes involved in familial bowel cancer.
1.2.5.3 Smoking
The prevalence o f smoking among UK adults is falling, possibly aided by the 
recent bans on smoking in public places introduced in Scotland and England & 
Wales(statistics, 2009). In spite o f this, smoking causes more than a quarter 
(29%) o f all cancer deaths in United Kingdom. More than one in five adults 
smoke and men are still likely to smoke than women(statistics, 2009). The 
average consumption of cigarettes per smoker per day is 14 in men and 13 in 
women and almost 40% o f the regular smokers start smoking regularly at the 
age o f 16 years(statistics, 2009). Around half o f all regular smokers die from 
the habit and half o f these in the middle age(Peto, 1994).
Smoking causes 90% o f lung cancers in men and 83% o f cases in women in 
the UK(al, 2006). Other environmental pollutants like asbestos could increase 
the risk o f  lung cancers in smokers. It is estimated that asbestos increases the
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risk o f lung cancer by around ten-fold in non smokers, while in smokers 
exposed to asbestos, there is a 100 fold increase in risk(Lee, 2001).
Exposure to environmental tobacco smoke also increases the risk o f  lung 
cancer. A recent meta-analysis showed that exposure o f environmental tobacco 
smoke at work or in the home increase the risk o f lung cancers among non- 
smokers by about a quarter, while heavy exposure double the risk(Stayner et 
al, 2007; Taylor et al, 2007). This exposure to environmental tobacco smoke 
has also been linked to other cancers like bladder and larynx(Bjerregaard et al, 
2006; Bosetti et al, 2008; Jiang et al, 2007).
Smoking is also an established risk factor for other cancers like those o f the 
oesophagus, larynx, pharynx, oral cavity, nasal cavity and sinuses, stomach, 
bowel, kidney and cervix(1986). Alcohol consumption in combination with 
smoking greatly increases the risk o f upper aero-digestive tract cancers(2004). 
The risk o f cancers of the upper aero-digestive tract in ex-smokers becomes 
lower than that o f  current smoker within five years, although risk is still higher 
than someone who has never smoked 20 or more years after stopping, and the 
risk o f bladder cancer is also higher than in never-smokers 20 years after 
giving up(Bosetti et al, 2008; Brennan et al, 2000; Brennan et al, 2001).
The role o f smoking in the pathogenesis o f breast cancer is controversial. 
Within the Million Women Study (a large UK prospective study), 224 917 
never smokers who completed a questionnaire were asked if  their parents had 
smoked and if  their current partner smoked. After a follow-up 3.5 years, 2518 
subjects developed invasive breast cancers. The adjusted relative risk o f breast 
cancer for passive exposure combined as a child and as an adult vs neither
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exposure was 0.98 (95% Cl 0.88-1.09). The results were similarly null for 
childhood exposure (0.98, 0.88-1.08) and adult exposure (1.02, 0.89-1.16) 
separately(Pirie et al, 2008).
In a cohort o f 78,206 women who were followed up prospectively, 3140 
reported diagnosis o f invasive breast cancer during follow-up. There was no 
increased risk o f development o f breast cancers in active and passive smokers. 
However it showed a modest 20% increase in risk o f breast cancer confined to 
women who began smoking before the age o f 17 years(Egan et al, 2002).
1.2.5.4 Anthropometry, exercise and diet
In Britain 67% of men and 52% o f women have a BMI o f 25 or more and 
approximately one fifth o f the men and women are obese(statistics, 
2003/2004). There is convincing evidence that obesity is associated with
increased risk o f cancers. In postmenopausal women increasing levels o f
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anthropometric variables including height, weight and BMI are associated with 
increased risk o f breast cancer(Lahmann et al, 2004; Reeves et al, 2007; van 
den Brandt et al, 2000). Obesity may increase levels o f sex hormones, insulin 
and insulin like growth factors which all in turn increase the risk o f breast 
cancer. By contrast premenopausal women with a BMI o f 31 or more have 
shown to have a 46% reduced risk compared to those with BMI o f less than 
21 (van den Brandt et al, 2000). This may be because obesity can disrupt 
ovulation(Key et al, 2004).
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Breast cancer risk is also affected by age at menarche and height, both of 
which are influenced by body weight earlier in life(Key et al, 2004). Obesity 
also increases the risk o f other cancers like endometrial cancer, colon cancer, 
oesophageal cancer and cancers o f the gall bladder and pancreas (Bergstrom et 
al, 2001; Bianchini et al, 2002; Moghaddam et al, 2007; Reeves et al, 2007).
Although it is difficult to separate the effects o f physical activity from those o f 
increased body weight, studies have shown that higher level o f physical 
activity reduced risk o f developing certain cancers which are independent of 
body weight. Two large cohort studies have shown reduced risk o f colon 
cancer (approximately 20-25%) with higher levels o f exercise(Friedenreich et 
al, 2006; Wei et al, 2004). Approximately 50 studies have looked into 
association between physical activity and breast cancer, showing that post­
menopausal women who are physically active have an 80% reduction in 
risk(Monninkhof et al, 2007). The risk o f breast cancer in industrialized 
countries is higher than in developing countries where the women are 
characterized with lower energy intake and higher energy expenditure. This 
could be related to lowering o f BMI or change in hormonal levels (Chan et al, 
2007; McTieman et al, 2004). Similar influence o f physical activity in 
premenopausal women is less clear (2007; Monninkhof et al, 2007).
A meta-analysis o f 7 cohort studies have shown 20% reduced risk o f 
endometrial cancer in most active women compared to the least active 
women(Voskuil et al, 2007). There is also limited evidence than increased 
physical activity could influence the risk o f developing lung and prostate 
cancer (Giovannucci et al, 2005; Nilsen et al, 2006; Patel et al, 2005; Tardon 
et al, 2005).
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1.2.5.5 Alcohol
Alcohol is a well excepted carcinogen and around 6% o f UK cancer deaths 
could be avoided if  people did not drink(PJ, 2003). Alcohol consumption 
increases the risk of cancers of the oral cavity, larynx, oesophagus, breast, 
bowel and liver and there is a direct correlation to the amount and the risk of 
cancer(Boffetta & Hashibe, 2006). Alcohol is thought to have a synergic 
relationship with tobacco in which the alcohol consuming smokers are 80 
times increased risk o f developing cancer o f the aero digestive tract(Franceschi 
et al, 1990). It is estimated that it would take 16 years for the risk o f  these 
cancers in a former drinker to fall to the level o f someone who has never 
consumed alcohol(Rehm et al, 2007). There is an estimated 5 fold increase in 
the risk o f liver cancer in people drinking more than 80gm per day for over 10 
years(Morgan et al, 2004). The risk o f rectal cancer is stronger with alcohol 
compared to rest o f the colon with almost doubling o f risk in people drinking 
more than 60g per day(Ferrari et al, 2007).
Emerging evidence indicates that drinking alcohol is correlated to the risk of 
breast cancer and the risk is increased by approximately 7% for every 
additional lOg/day of alcohol (Hamajima et al, 2002). Two meta-analysis of 
epidemiological studies, one carried out in 1994(Longnecker, 1994) and the 
other carried out through 1999(Ellison et al, 2001) showed an increase in the 
relative risk o f breast cancer with alcohol consumption. Both studies showed a 
modest relation o f alcohol consumption to risk o f breast cancer, with a 10% 
risk being seen in women reporting approximately one alcoholic drink per day 
as compared to non-drinkers. This could be mediated by an increase in the 
oestrogen levels(Boffetta & Hashibe, 2006). Another mechanism is thought to
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be the stimulation o f cytochrome P-450 microsomal enzyme by alcohol which 
is involved in procarcinogen activation.
As with coronary artery disease, moderate amount o f alcohol is thought to 
have protective effect against certain cancers like kidney cancers(Lee et al, 
2007).
1.2.5.6 Diet
Fruit and vegetable contain antioxidants and are thought to be protective 
against certain cancers. Each daily portion o f 80-100 grams o f fruit or 
vegetables halves the risk o f oral cancer(Pavia et al, 2006), reduces the risk o f 
squamous cell cancer o f the oesophagus by approximately 20% and stomach 
cancer by about 30%(Freedman et al, 2007). High folate intake has been 
shown to reduce risk o f  breast cancer in moderate and heavy drinkers(Larsson 
et al, 2007). High fibre diet is thought to be protective against bowel cancer. 
This is particularly protective in people who consume high amounts o f red and 
processed meat (Norat et al, 2005). High intake o f salt and salt-preserved 
foods are associated with increased risk o f stomach cancer (Shikata et al, 
2006). A recent collective analysis o f cohort studies found a 16% reduction in 
risk o f bowel cancer in people with higher consumption o f milk, which 
remained after adjustment for total calcium and vitamin D intake(Cho et al, 
2004).
Contrary to the earlier belief that dietary fat has no relation to the incidence of 
breast cancer, recent studies suggest a link. In a recent cohort o f  pre­
menopausal women higher intake o f animal fat was associated with increased
57
risk o f breast cancer(Cho et al, 2003b) and a pooled analysis o f nine breast 
cancer cohort studies reported a 9% increased risk with each 5% increase in 
saturated fat(Smith-Wamer et al, 2001). Lack of association between fat and 
breast cancer in some o f the previous cohort studies has been attributed to 
inaccuracy in reporting diet(Bingham et al, 2003).
1.2.5.7 Exogenous hormones
Abnormal hormone levels have been associated with some o f the common 
female cancers. Early menarche and late menopause has been associated with 
increased risk o f ovarian, endometrial and breast cancers(2002; Albrektsen et 
al, 2005). Each full term pregnancy has a protective effect against these 
cancers and first full term pregnancy providing more protection than 
successive ones(Albrektsen et al, 2005). Breast cancers are reduced by around 
4% for each year a women breastfeeds(2002). In women who breast feed there 
is also a 50% reduction in the risk o f endometrial cancer(Newcomb & 
Trentham-Dietz, 2000) and 40% reduction in ovarian cancer(Tung et al, 2005).
In 1996, a meta-analysis o f data from 54 epidemiological studies of oral 
contraceptive use and risk o f breast cancer showed that subjects taking oral 
contraceptives have a slightly increased risk o f  breast cancer compared to the 
risk in non-users(1996). Data o f over 53000 women with breast cancer from 
different countries were collected, checked and analyzed. The risk decreased 
with increasing years after stopping the oral contraceptives and there was no 
evidence o f increased risk o f having breast cancer diagnosed 10 years or more 
after stopping the use o f oral contraceptives and the cancers diagnosed were
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less advanced than in never users. Although there is a transient increase in 
breast cancer when oral contraceptives are taken(1996; Boyle et al, 2003), a 
meta-analysis o f  European case-control studies indicated that use o f oral 
contraceptive for five or more years results in a 50% reduction in risk of 
ovarian cancer which remains for more than 20 years(Bosetti et al, 2002). 
Similar reduction in endometrial cancer has been noted in case control studies 
with reduction in risk increasing with duration o f use(J, 1996).
There is extensive data linking hormone replacement therapy to the risk o f 
breast cancer. It is estimated that over the past decade the use o f HRT by UK 
women aged 50-64 years has resulted in an extra 20,000 breast cancers(Beral, 
2003). The collaborative group in 1997 published the meta-analysis o f 
approximately 90% o f worldwide epidemiologic evidence on the relation 
between the risk o f breast cancer and the use o f  HRT(1997). It involved over 
52,000 cancer cases and 108,000 controls. Among current users and those who 
used HRT within 1 to 4 years previously, the risk of having breast cancer 
diagnosed increased by 2.3% for each year o f use and the relative risk was 
1.35 for women who used HRT for 5 or more years. However the effect 
disappears 5 years after stopping HRT.
A randomized controlled primary prevention trial involving over 16,000 
postmenopausal women aged 50-79 years receiving combined hormone 
preparation showed an increased risk o f  breast cancer in the users by 26%. The 
incidence o f coronary heart disease was also increased by 29%(Rossouw et al, 
2002). The risk o f  colorectal cancer and hip fractures were reduced by 30%. 
Overall the risks exceeded the benefits o f the use of combined oestrogen plus 
progestin preparation.
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Risk ratio o f breast cancer in women taking combined or oestrogen only 
therapy is 2 and 1.3 respectively(Beral, 2003). The risk increases with duration 
o f use, with risk ratio o f  2.3 for 10 or more years o f combined HRT, compared 
with 1.5 for less than 1 year. There is no difference in risk between never users 
and women who stopped therapy at some point in the previous 5 years.
Oestrogen only HRT are also associated with increased risk o f endometrial and 
ovarian cancers(Lacey et al, 2002). The risk o f endometrial cancer is doubled 
after 5 years o f their use and similar use produces a 25% increased risk o f 
ovarian cancer(J, 1996; Pike et al, 2004). Studies have shown than the use o f 
combined pill does not increase the risk o f both these cancers(Lacey et al, 
2002; Pike et al, 2004). Abnormal hormone levels have been associated with 
male cancers as well. There appears to be a more than two-fold increase in risk 
o f prostate cancer in men with highest testosterone levels(Shaneyfelt et al, 
2000).
1.2.5.8 Occupation and cancer risk
It is estimated that 11% o f all cancer cases in men were caused by 
occupational exposure and approximately 4% of cancer deaths in men were 
caused by occupation(IARC, 2008; Winther et al, 1997). The cancer most 
commonly linked to occupation is mesothelioma and 80-90% of mesothelioma 
cases in men are linked to occupational exposure to asbestos (IARC, 2008; 
Rushton 1, 2008; Winther et al, 1997). The other cancer which is strongly 
linked to occupation is cancer o f nasal cavity and sinuses. The important 
workplace exposure for this cancer is leather dust, wood dust and 
metals(IARC, 2008; Winther et al, 1997). Lung cancer also has a strong 
occupational component, with up to 17% o f deaths in men and 5% in women
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caused by workplace exposure(Rushton 1, 2008). The major causes of 
occupation related lung cancer are metals, asbestos, radon, arsenic, silica and 
polycyclic aromatic hydrocarbons (PAH)(IARC, 2008; Pelucchi et al, 2006; 
Rushton 1, 2008). A small proportion o f bladder cancers are linked to 
occupation and occupational exposure to PAH and other aromatic amines as in 
rubber industry. Laryngeal cancer has been linked to PAH and leukemia to 
benzene and other solvents. Other possible occupational exposures leading to 
cancer include vinyl chloride to liver cancer(Boffetta et al, 2003) and diesel 
engine exhaust exposure to lung cancer(Lipsett & Campleman, 1999).
The relationship between ionizing radiation and the risk o f breast cancer is 
well established (Evans et al, 1986; John & Kelsey, 1993). Increased risk has 
been observed in patients receiving fluoroscopy for tuberculosis and radiation 
treatment for medical conditions. The risk is inversely associated with age at 
exposure. Women treated for Hodgkin’s disease by the age o f 16 have a 
subsequent risk o f  developing breast cancer as high as 35% by the age o f 40 
years(Bhatia et al, 1996; Hancock et al, 1993). Higher dose o f radiation and 
treatment between the ages o f 10 and 16 corresponded with higher risk. The 
risk o f breast cancer is also raised when radiation therapy was given in the late 
teens and twenties, but to a lesser degree. In these studies majority o f breast 
cancers (85-100%) developed either within the field o f  radiation or at the 
margin(Sankila et al, 1996).
In subjects at high risk o f developing breast cancer intensive mammographic 
screening has been advocated. It is unknown whether the additional radiation 
exposure could produce increased risk. In theory, breast cancer patients treated 
with lumpectomy and radiation therapy should be at an increased risk o f
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second cancers compared to those treated by mastectomy. However outcome 
studies with long follow-up (15 years) does not show any difference (Obedian 
et al, 2000).
1.2.5.9 Infections and cancer
Several infectious agents are considered to be causes o f cancer in humans. The 
estimated total o f  infection-attributable cancer in the year 2002 is 1.9 million 
cases or 17.8% of the global cancer burden (Parkin, 2006). The principal 
agents are the bacterium Helicobacter pylori (5.5% o f all cancer), the human 
papilloma viruses (5.2%), the hepatitis B and C viruses (4.9%), Epstein-Barr 
virus (1%), human immunodeficiency virus (HIV) together with the human 
herpes virus 8 (0.9%). Relatively less important causes o f cancer are the 
schistosomes (0.1%), human T-cell lymphotropic virus type I (0.03%) and the 
liver flukes (0.02%). There would be 26.3% fewer cancers in developing 
countries (1.5 million cases per year) and 7.7% in developed countries 
(390,000 cases) if  these infectious diseases were prevented. Table below 
shows some o f well known infections associated with cancer.
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Table 1.1
Infection C ancer site/type
Human papilloma virus (HPV) Cervix, anus, lower genital tract, 
pharynx, other head & neck
Hepatitis B and C virus (HBV, 
HCV)
Liver, NHL
Helicobacter pylori (Hp) Gastric cancer, gastric MALT*
Schistosomes and liver flukes Liver, bladder, colon
HIV Kaposi sarcoma, NHL, 
Hodgkinlymphoma
Human herpes virus 8 (HHV8) Kaposi sarcoma, NHL
Epstein Barr virus (EBV) Hodgkin lymphoma, Burkitt NHL
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1.2.6 Immune response to cancer
Evidence supporting an immune response to cancer is compelling due to the 
identification o f autoantibodies against a number o f intracellular and surface 
antigens in patients with cancer referred to as tumour-associated antigens 
(TAAs)(Crawford et al, 1982; Lubin et al, 1993; Winter et al, 1992). Studies 
show antibodies to TAAs identified before symptomatic disease (Li et al, 
2005; Robertson JFR, 2005a; Robertson JFR, 2005c). Low levels o f TAAs can 
elicit a detectable antibody response and its detecting appears more promising 
than direct protein screening which is less sensitive and specific(Luborsky et 
al, 2005; Nesterova et al, 2006). Our review will look into the present 
modalities available in the identification o f TAAs which initiates the antibody 
response.
The productive mechanism o f these antibodies is less well understood. Usual 
targets are often cellular proteins which have altered location and/ or post- 
translational modifications which have led to tumourogenesis(Scanlan et al, 
2001). How these intracellular molecules acquire immunogenicity is not 
entirely clear. Antibodies to p53 is one o f the earliest and the most intensely 
investigated and we intend to review some o f the important studies in this field 
which may shed light into the mechanism o f production o f autoantibodies. We 
will also look into some o f the more recent antigens identified to play an 
important role in cancer diagnosis.
Hundreds o f autoantigens have been cloned with the recognition o f 
autoantibodies in patient’s sera (Boon & Old, 1997; Forti et al, 2002; Sahin et 
al, 1995; Scanlan et al, 2001). However to predict the malignant disease based
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on the presence o f these individual antibodies have been largely unsuccessful 
and demonstrating their tumour relevance has been difficult(Brandt-Rauf & 
Pincus, 1998). Since more than one antigen is often associated with a 
particular cancer, panels o f antigens to improve the diagnostic potential are 
being evaluated.
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1.2.6.1 Tumour associated antigens and their detection.
Old and colleagues initially demonstrated the presence o f tumour-specific 
antibodies in the serum of cancer patients (Old, 1981). However major 
improvement in identification o f various tumour associated antigens did not 
materialize until early to mid 1990’s when a technique to identify T and B-cell 
epitopes uniquely expressed on tumour cells was developed. Initially Boon and 
colleagues popularized the T-cell screening o f a cDNA expression library 
made up of m-RNA from the tumour cells(van der Bruggen et al, 1991). This 
technique and its modification led to the identification o f more than 50 
antigens, most o f which were identified in malignant melanoma. In 
concordance with this genetic approach, a more biochemical approach was 
found to be successful. Here antigenic peptides pool eluded from the cell- 
surface HLA molecules o f the tumour cells were fractioned by liquid 
chromatography and individual fractions were screened with tumour-specific 
T-cell clones(Cox et al, 1994; Wang, 1999). However the most recent and 
popular technique is the SEREX (serological analysis o f recombinant cDNA 
expression libraries) and its implementation dates from 1995(Sahin et al, 
1995). With the introduction o f SEREX a large number o f TAAs have been 
identified (over 2000). In this antibody based method cDNA clones were 
constructed from tumour tissue specimens recognized as autoantigens by 
autologous cancer patient sera(Chen et al, 2005; Sahin et al, 1997; Sahin et al, 
1995; Tureci et al, 1997). An advantage o f SEREX over other techniques is 
that by identifying immunogenic proteins uniquely expressed in tumours, these 
immunogenic proteins may also contain T-cell epitopes which could be
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identified as well. Antigen specific cellular and humoral immune response can 
occur simultaneously against tumour associated antigen. This has been found 
to be true with number o f antigens including breast cancer antigens HER2 and 
NY-ESO-l(Jager et al, 1998). However it has its own disadvantages and such 
expression libraries contain not only cDNA clones from tumour cells but also 
from inflammatory and other cellular infiltrates, and thus being dependent on 
the particular patient(Femandez Madrid et al, 2005). It fails to employ criteria 
to select those antigens recognised by multiple patients. Another disadvantage 
is that since SEREX involves screening tumour-derived autologous cDNA 
libraries, it may have a bias towards identifying autoantigens that are over 
expressed but otherwise normal antigens rather than mutated in tumour 
cells(Femandez Madrid et al, 2005). Thus they may not preferentially select 
antigens that are oncogenic. As a result antigens which are expressed in low 
abundance but more relevant to tumorigenesis may be missed.
To negate these problems, researchers have used the approach o f using cDNA 
clones constructed from immortalized cell lines and screening with antibodies 
from multiple cancer sera (Fernandez Madrid et al, 2005; Imai et al, 1993a). 
This method could minimize the confounding effect o f irrelevant antibodies 
and has a potential o f revealing a number o f proteins that may be involved in 
cellular functions related to tumourogenesis.
Another method used in the identification o f tumour associated antigens is the 
proteomics approach (Klade et al, 2001). This allows individual screening of 
large number o f  sera and at the same time identify a large number o f 
autoantigens(Zhang, 2004). Here lysates from cancer cell lines are separated 
on two-dimensional gel electrophoresis, transferred to membranes, and probed
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with cancer sera and immuno-reactive proteins identified by mass 
spectrometry (Canelle et al, 2005; Klade et al, 2001; Le Naour et al, 2001; 
Yang et al, 2007). This approach allows proteins, in their post-translational 
modification states as they occur in cells, to be analyzed for their 
antigenicity(Qiu et al, 2008).
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1.2.7 Antibodies to Cancer antigens
1.2.7.1 Antibodies to traditional well recognised antigens in the 
diagnosis of cancer
A number o f well recognised antigens to which tumour associated antibodies 
have been detected will be described in this chapter..
7.27.7.7 P53
P53 is a phosphoprotein not easily detectable in the nucleus o f normal 
cells(Benchimol et al, 1982). It arrests cell cycle progression following DNA 
damage caused by cellular stress by activating a series o f genes involved in 
cell cycle regulation(Kastan et al, 1991). It thus allows the DNA to be repaired 
or leads to apoptosis(Yonish-Rouach et al, 1991). However cancer cells which 
bear a mutant p53 are unable to exhibit its normal functions leading to 
insufficient DNA repair and thus leading to genetically unstable cells(Giaccia 
& Kastan, 1998; Levine, 1997; Oren & Rotter, 1999; Prives, 1998). In human 
cancers, p53 tumour suppressor gene is the most frequently identified site for 
mutations accounting for more than 50% of cases(Hofseth et al, 2004; Soussi, 
2000b).
In 1979 the importance o f p53 in tumourogenesis was reported from several 
laboratories(DeLeo et al, 1979; Linzer & Levine, 1979). Subsequently during 
the course o f a tumour-associated antigens screening, Crawford et al in 1982 
identified p53 antibodies against human p53 protein(Crawford et al, 1982). In
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this study (Crawford et al), 14 out o f  the 155 (9%) sera from breast cancer 
patients tested were positive for anti-p53 antibodies and no positives were 
detected among 164 control sera from normal women. Later, Caron de 
Fromentel et al found that p53 autoantibodies in wide variety o f tumours in 
children with an average frequency o f 12% and in certain tumours reaching 
approximately 20%(Caron de Fromentel et al, 1987). Soussi et al compiled a 
large group o f studies involving serological analysis o f p53 in different types 
o f  cancer(Soussi, 2000a). They analysed almost 9500 patients with different 
types o f cancer and also included controls composed o f approximately 2500 
individuals with no evidence o f cancer. P53 was found to be strong markers 
for malignancy which was highly statistically significant (P<0.001) with a 
specificity o f 96%. The sensitivity of such detection was 30%.
Mutation in p53 gene has been implicated in the development of 
immunogenesis. In the above study by Soussi et al involving a wide variety o f 
cancers it was found to be associated significantly with most types o f cancers 
with a few exceptions o f testicular cancer, melanoma and hepatocellular 
carcinoma which were negative for p53 auotoantibodies(Soussi, 2000a). These 
three cancers are well known to be devoid for p53 mutations(Fleischhacker et 
al, 1994; Lubbe et al, 1994; Puisieux et al, 1993).
Mutation in the p53 gene or accumulation o f mutant p53 protein has been 
identified in common premalignant lesions and in histologically normal tissue 
adjacent to tumours. This may suggest that they are early events in the process 
o f carcinogenesis(Downing et al, 2003; Harris, 1996; Hill & Sommer, 2002).
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Further studies on other cancers since then have shown a good correlation 
between the presence o f p53 autoantibodies in the sera o f patients with cancers 
and the occurrence o f p53 mutation or accumulation o f mutant p53 protein in 
the tumour tissue(Soussi, 2000a; Soussi, 2000b). Study on patients with 
premalignant conditions like leukoplakia and Barrett’s oesophagus has shown 
p53 antibodies in their sera suggesting its potential use in early 
diagnosis(Soussi, 2000a). Autoantibodies to p53 have also been identified in 
cases o f heavy smokers before their development o f lung and other tobacco 
related cancers and also in certain workers who have been exposed to 
carcinogens before their development o f cancer(Lubin et al, 1995; 
Schlichtholz etal, 1994; Trivers et al, 1996).
In 1992 an important study by Winter et al on correlating p53 mutations with 
appearance o f antibodies in lung cancer patients was published(Winter et al, 
1992). Cancer cell lines from patients with lung cancer were analysed for 
mutations. Here, sera o f 13% (6/46) o f  patients with lung cancer were found to 
be positive for p53 antibodies and all o f them had point mutations (missense 
mutations), which resulted in accumulation o f p53 proteins with altered 
function and relatively increased stability. These missense mutations occurred 
in the hot spot regions o f p53 in exons 4 to 9. Patients with other forms of 
mutations like stop codon mutations or frameshift mutations failed to induce 
antibody response. However contrary to the expectations, the analysis o f p53 
antibody specificities revealed that the antigenic determinants o f p53 were 
located at the amino-and carboxy-terminal regions and away from the central 
region of p53 containing the mutations(Labrecque et al, 1993; Lubin et al,
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1993). Absence o f antibodies in patients with other mutations (stop codon or 
frameshift mutations) in the study by Winter et al would be related to the 
relative absence o f p53 protein in the transformed cells. Thus the load o f the 
aberrant protein appears to be an important factor in development o f antibody 
response. The inactive mutant p53 protein is associated with increased stability 
with half life o f several hours compared to 20 minutes for wild type 
p53(Soussi, 2000a). Another factor which may decide the antigenic stimulus 
could be the location of the p53 protein. It is normally located in the nucleus, 
and in cancer cells this protein can be excluded from the nucleus and could 
appear in the cytoplasm as well(Moll et al, 1992). Even with all the 
information, the mechanism behind the antigenicity o f p53 is far from clear. 
Several studies have shown that despite similar types o f cancer, identical p53 
mutations, and p53 accumulation, some patients could be either positive or 
negative for p53 antibodies(Hammel et al, 1999; von Brevem et al, 1996; 
Winter et al, 1993). This would suggest that other factors are contributing to 
humoral response and there is appears a possibility that it could be linked to 
the biological make up o f the patients(Soussi, 2000a).
1.2.7.1.2 HER2
Like tumour suppressor genes, oncogeness represent the other class o f  genes 
contributing to tumour development(Aaronson, 1991). Human epidermal 
growth factor receptor-2 (HER-2) is an important member o f the oncogene 
family(Coussens et al, 1985). The gene product in HER-2/neu gene function as 
a normal epithelial protein in cell growth and proliferation(Camey et al, 2003). 
However their gene amplification and protein over expression contribute to 
converting healthy cells to cancer cells and the oncoprotein is now recognized
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as an important factor in breast cancer development(Camey et al, 2003). HER- 
2/neu DNA amplification and protein overexpression occur in 25-30% of 
women with primary breast cancer(Ross & Fletcher, 1999; Schaller et al, 
2001). Patients with pre-invasive cancers are associated with high IHC 
staining for HER-2. Latta et al reported 34 % IHC staining in patients with 
pure DCIS and sixty percent o f  cases o f high grade ductal carcinoma in-situ 
showed increased IHC overexpression(Latta et al, 2002). The extra cellular 
domain (ECD) o f the receptor protein has been found to be shed in plasma and 
serum o f healthy individuals and patients with breast cancer(Leitzel et al, 
1992; Pupa et al, 1993; Zabrecky et al, 1991). In a systematic review by 
Carney et al the analysis o f 1923 primary breast cancer patients from various 
studies showed increased ECD concentration in 18.5% of patients at the time 
o f cancer diagnosis(Camey et al, 2003). Although found to be useful in the 
diagnosis o f  primary breast cancers, observations points to their concentration 
being closely linked to tumour burden. In metastatic disease a review o f 45 
references and 4622 patients with metastatic breast cancer showed that 43% of 
patients had raised ECD values(Camey et al, 2003). Likewise a report by 
Anderson et al showed that significantly more patients with recurrent breast 
cancer have raised ECD (59% - 55 o f 93) compared to primary breast cancer 
patients (8%), and importantly in patients with recurrent disease, ECD 
concentrations were detected significantly more often in patients with distant 
metastases than those with local metastasis ( 68% vs 19%)(Andersen et al, 
1995).
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1.2.7.1 .3  c-myc
Almost all types o f human malignancy have been reported to have 
amplification and /or over expression o f the c-myc gene(Nesbit et al, 1999). It 
is now known that the c-myc gene participates in most aspects o f cellular 
function, including replication, growth, metabolism, differentiation and 
apoptosis(Dang, 1999; Dang et al, 1999; El end & Eilers, 1999; Hoffman & 
Liebermann, 1998; Packham & Cleveland, 1995; Prendergast, 1999). c-myc 
gene produces three major proteins named c-myc 1, c-myc 2 and c-myc 
S(Facchini & Penn, 1998; Henriksson & Luscher, 1996). c-myc 2 is 
approximately 62-kDa protein that is the major form of the three c-Myc 
proteins and the one referred to as ‘c-Myc’ in most studies. There is increasing 
evidence to support a role for c-myc proto-oncogene in tumour onset and 
progression. In breast cancer, the chromosome 8 region where the gene is 
localized has been identified as one o f the three most commonly amplified 
regions o f the genome(Couijal et al, 1997). This region is commonly amplified 
in small cell lung carcinoma, leukemia and colon carcinoma(Alitalo et al, 
1983; Dalla-Favera et al, 1982; Little et al, 1983). Studies utilizing 
immunohistochemistry show that about 50-100% of breast cancer cases have 
increased levels o f c-myc proteins(Agnantis et al, 1992; Hehir et al, 1993; 
Pavelic et al, 1992; Saccani Jotti et al, 1992).
1.2 .7 .1 .4  A nnexins
They are a family o f calcium and phospholipids-binding, membrane 
associate proteins found in various organisms and implicated in ca2+ signal 
transduction process associated with cell growth and differentiation(Ahn et al,
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1997; Brichory et al, 2001; Chetcuti et al, 2001; Emoto etal, 2001b; Mai et al, 
2000; Maler et al, 2002; Srivastava et al, 2001; Yeatman et al, 1993). 
Annexins are classified into five groups, A-E, and within each o f these groups, 
individual annexins are identified numerically. Human annexins belong to 
group A which has been sub-classified from 1 to 13(Mussunoor & Murray, 
2008). Some annexins are over-expressed in specific types o f cancers, while 
others show consistent loss o f expression. There is increasing evidence that 
changes in annexin expression and/ or their subcellular localization contribute 
to development and progression o f cancer(Mussunoor & Murray, 2008). 
Annexin 1 is found to be over-expressed in oesophageal adenocarcinoma, 
pancreatic adenocarcinoma, colorectal carcinoma and hairy cell 
leukemia(Mussunoor & Murray, 2008). However in oesophageal squamous 
cell carcinoma and breast adenocarcinoma and prostatic cancer there is loss o f 
annexin A l expression(Mussunoor & Murray, 2008). Increased expression o f 
annexin A2 has been described in several types o f tumours, including gastric 
cancinoma, colorectal cancer, pancreatic cancer, breast cancer, high grade 
gliomas, kidney cancers and vascular tumours(Duncan et al, 2008; Emoto et 
al, 2001a; Emoto et al, 2001b; Esposito et al, 2006; Reeves et al, 1992; 
Sharma et al, 2006; Syed et al, 2007; Zimmermann et al, 2004). In contrast 
there is loss o f expression o f this annexin in other types o f tumours, including 
prostatic carcinoma and pulmonary metastasis o f osteosarcoma(Gillette et al, 
2004; Kang et al, 2002; Stewart et al, 2007; Yee et al, 2007). AAbs to 
annexin 1 and annexin 2 have been investigated in patients with lung cancer. 
In a study by Brichory et al (methodology), 2001 looking into 54 lung cancers, 
Annexin 2 were found in 33% of lung cancer patients(Brichory et al, 2001).
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Over all 60% o f lung cancer patients had annexin 1 and/or annexin 2 AAbs 
present. The reactivity seen in lung cancer was not limited to advanced stages, 
and 51% o f patients with stage 1 cancer had AAbs. In another study by Qui et 
al, involving 85 patients with lung cancer with preclinical samples collected 
with 1 year before the diagnosis o f lung cancer matched with high risk controls 
showed significant antibody reactivity against annexin 1 and other two 
antigens (LAMR1, 14-3-3 theta) with a sensitivity o f 55% and specificity of 
95%(Qiu et al, 2008). When comparing the reactivity o f samples taken 
between 0 and 6 months before diagnosis and the other group between 7-12 
months before diagnosis there was equal reactivity between two groups in 
annexin 1.
Annexin X IA  has been reported to be reactive in a high proportion o f sera o f 
patients with DCIS, even higher than those with invasive cancer(Femandez- 
Madrid et al, 2004). A study by Femandez-Madrid, 2004 micro-arrays 
containing the T7 phages encoding the potential breast TAAs were probed 
with serum from 90 patients with breast cancer (15 with DCIS and 75 with 
1DC), along with 51 non-cancer control sera and sera from 21 patients with 
systemic autoimmune disease. One o f the antigens identified corresponded to 
annexin XI-A and although the number o f patients with DCIS was small,
AAbs to these antigens were present in 60% o f patients with DCIS suggesting 
a strong link between annexin XI-A and early development o f cancer. Eleven 
percent o f patients with IDC had positive AAbs to annexin XI-A and no 
reactivity was reported in autoimmune samples.
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1.2.7.1 .5  PSA
PSA is a kallikein which belongs to the family o f serine proteases expressed at 
high levels in the epithelium o f the human prostate gland(Malm & Lilja, 
1995). PSA as a tumour marker is invaluable in the diagnosis and post surgical 
management o f prostate cancer. It has been established that prostate cancer 
patients have a greater fraction o f PSA complexed to ACT(alpha 1 
antichromotripsin) and the ratio o f free to total PSA has become more 
important for distinguishing benign and malignant prostatic 
pathology(Armbruster, 1993). In is now evident that hormonally regulated 
tissues in females like breast can produce PSA(Yu et al, 1996). With the use o f 
ultrasensitive immunoassays, PSA has been demonstrated in at least 50% of 
normal female sera(Melegos & Diamandis, 1998). The concentration o f PSA 
in female sera is approximately 1000-fold lower than that o f the breast and is 
approximately 100-500 times lower than male serum PSA(Black & 
Diamandis, 2000). The serum PSA in women is inversely correlated with age 
and is probably related to the hormonal levels and PSA has been found to be 
differentially expressed during menstrual cycle(Zarghami et al, 1997). It is 
also seen in milk o f lactating women and nipple aspirate fluid(Foretova et al, 
1996; Sauter et al, 1996). While level of serum PSA is elevated in both benign 
and malignant breast disease, molecular form of circulating PSA differs in 
women with and without breast cancer. The predominant serological form 
(>50%) o f PSA in a significant proportion o f females with breast cancer is free 
PSA(Black et al, 2000). In a study by Black et al, in patients with breast 
cancer, benign breast disease and normal’s, the percentage o f breast cancer 
patients with free PSA as predominant (>50% o f the total PSA) form was five
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times higher compared to benign breast disease or healthy women(Black et al, 
2000). Free PSA as the predominant molecular form showed a sensitivity o f 
20% and a specificity o f 96%. The study also showed a dramatic reduction of 
free PSA following surgery, and this is a strong indication that this fraction is 
produced by breast tumours.
1 .2 .7.7.6NY-ESO-1
NY-ESO-l is classic cancer/testes (CT) antigen discovered during a SEREX 
analysis o f an oesophageal cancer(Chen et al, 1997a). NY-ESO-l is a 22 kD 
hydrophobic protein coded for by a gene in the Xq28 region(Chen et al,
1997a). In normal tissues, expression o f NY-ESO-l mRNA as detected by RT- 
PCR is predominantly restricted to the testes, whereas in cancer it is found in 
variable proportion in a wide range o f different malignancies including 
melanomas, cancer o f the breast, ovary and lung(Chen et al, 1997a). In a 
report by Sugita et al, using conventional RT-PCR, they found NY-ESO-l 
mRNA in 37 o f 88(42%) breast cancer specimens(Sugita et al, 2004). NY- 
ESO-l antigens are strongly immunogenic, and may produce specific 
hormonal and cellular immunity in patients with NY-ESO-l expressing 
cancer(Chen et al, 1997b; Jager et al, 1998). In a recent study 4% of breast 
cancer patients produced detectable antibodies against NY-ESO-l (Mischo et 
al, 2006). Melanomas studies have shown a better antibody response and 
approximately 50% of patients with advanced NY-ESO-l mRNA-positive 
melanoma produce NY-ESO-l antibody(Chen et al, 1997b). In a study by 
Stockert et al involving sera o f 234 cancer patients and 70 normal controls,
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antibodies to NY-ESO-1 in 19 patients, to MAGE-1 in 3, MAGE-3 in 2, and to 
SSX2 in 1 patient. No reactivity to these antigens was found in sera from 70 
normal individuals(Stockert et al, 1998). The frequency of NY-ESO-1 
antibody was 9.4% in melanoma patients and 12.% in ovarian cancer 
patients324.
1.2.7.2 Antibodies to new antigens useful in the diagnosis of 
lung cancer
With the introduction o f SEREX, hundreds o f  new cancer related antigens 
have been identified. However, only a few o f them are presently used in the 
potential diagnosis o f early cancer and those used in our panel are described.
1.2 .7 .2 .1C  AGE
It is a cancer testes antigen like NY-ESO-1 which has been reported as capable 
o f producing antibody response to lung cancers(Chapman et al, 2008). GBU4- 
5, like CAGE encodes a DEAD-box domain and has recently been described 
to produce antibody response in lung cancers(Chapman et al, 2008). These 
DEAD-box-containing proteins are involved in RNA processing, ribosome 
assembly, spermatogenesis, embryogenesis, and cell growth and division. 
They seem to be immunogenic, cancer-specific and provide diagnostic and 
potentially immunotherapeutic cancer targets. Analysis o f  autoantibodies to 
the full panel o f seven antigens resulted in 75% o f the lung cancer samples 
being identified and 92% of squamous cell carcinomas with a specificity for 
cancer o f 92%(Chapman et al, 2008). In this study, autoantibody response to 
DEAD-box proteins CAGE and the new cDNA GBU4-5 were also highly
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sensitive and specific in this study. The DEAD-box cancer testes antigen 
CAGE has previously been shown to be expressed in a number o f other 
cancers, and autoantibodies has been reported in gastric and pancreatic cancers 
apart from lung cancers. However, autoantibodies to GBU4-5 have not been 
investigated in other cancers.
1 .2 J .2 .2  SOX2
It is an amplified oncogene in lung carcinomas. It is expressed in the 
developing foregut, where it regulates initial dorsal-ventral patterning, shapes 
epithelial-mesenchymal interactions and is required for proper differentiation 
both o f the squamous oesophageal and of multiple respiratory cell types(Bass 
et al, 2009). It is also preferentially expressed in squamous cell carcinomas of 
the oesophagus and anal canal compared to adenocarcinomas from these 
sites(Long & Homick, 2009). SOX antibodies have been found to specific 
serological markers for small cell lung cancers and have a reported sensitivity 
o f 43% in this group which represent 13-20% o f lung cancers(Titulaer et al, 
2009).
1.2 .7 .2 .3G  BU 4-5
GBU 4-5, like CAGE encodes a DEAD-box domain and has been identified to 
express antibody response in lung cancers(Chapman et al, 2008). It has been 
identified using SEREX technologies(Tureci et al, 2005). These proteins have 
been thought to be involved in embryogenesis, cell growth and division, and 
may have a role to play in carcinogenesis(Linder, 2006). They are
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immunogenic, cancer specific and may provide diagnostic and potentially 
valuable targets for cancer immunotherapy(Park et at, 2003).
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1.2.8 Autoantibodies to panel of antigens in cancer diagnosis
Cancer is a heterogeneous disease with variation in individual antigen 
expression between patients. Although detection o f individual antigens have 
been shown to have diagnostic potential, it is likely that the reliability o f  a test 
could be improved by identifying group of antigens which are associated with 
particular cancer. The first report o f using a panel o f antigens was from our 
centre (Robertson et al Blood Borne Tumour Markers, patent W099/58978). 
Zhang et al in their study used enzyme immunoassay to look into 7 different 
types o f antibodies in sera o f 527 patients with 6 different types o f 
cancers(Zhang et al, 2003). The antibody frequency o f any individual antigens 
varied from 15-20%. However a stepwise increase in the positive reaction was 
noted on successive addition o f seven different antigens to the panel. There 
was a rise in the level o f antibody against at least one antigen in 51% o f cases. 
For different cancers there was a variation in the percentage of antibodies 
detected against various antigens. For breast cancer it appeared that c-myc and 
Koc antibodies were more frequently detected than other antibodies. However 
for lung cancer antibodies to cyclin Bl,p62 and p53 were more frequently 
detected. For prostate cancer there was a high frequency o f antibodies to p62 
and cyclin B l.
In another study by Megliorino et al, sera from 1137 patients with different 
types o f cancers were analysed for antibodies to survivin(Megliorino et al, 
2005). They were positive in 8.4% (96/1137) o f cases. From this large group 
o f cancer cases, sera o f a subgroup o f 546 cancer patients were analysed for 
antibodies to p53, c-myc and survivin. The study showed that when antibody 
to any one o f the antigens was considered, the cumulative frequency was
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increased to 27% from an individual maximum o f 12%. This was significantly 
higher compared to normal sera which was positive in 4.9 % o f subjects. 
Interestingly the rate o f antibody frequency was particularly high in certain 
cancers notably lung (32%), HCC(39%), and gastric cancer (31%). There was 
a different pattern of antibody frequency in individual cancer types i.e for 
breast cancer, c-myc was a better reactive antigen than p53 and survivin, in 
oesophageal and lung cancer both p53 and c-myc appeared more reactive, for 
colorectal cancer the most reactive antigen was p53.
TAAs p62 and Koc are insulin-like growth factor 11 (IGF-11) messenger RNA 
binding proteins. In a study by Zhang JY et al, sera from 777 patients with 10 
different types o f cancers were assessed for antibodies to p62 and Koc(Zhang 
et al, 2001). Individually autoantibodies to p62 and Koc were found in 
approximately 12% o f patients. The cumulative frequency was increased to 
21% and compared to normal controls and those with autoimmune disease it 
was statistically significant (p<0.01).
In a similar study by Stockert E et al, sera o f 234 patients with different types 
o f cancer and 70 normal individuals were analyzed for antibodies to seven 
different antigens(Stockert et al, 1998). Antibodies to 4 different antigens were 
found to be raised in cancer patients and none in normal controls. In particular, 
7.7% (2/26) o f patients with breast cancer and 4.2 %( 1/24) o f patients with 
lung cancer had raised antibodies to NY-ESO-1. This was detected in higher 
frequency in melanoma patients (9.4%; 12/127) and ovarian cancer (12.5%;
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4/32). There was no evidence in this publication that a panel of autoantibodies 
was additive.
Roberson JFR et al in his report involving approximately 200 primary breast 
cancers, reported a sensitivity o f 82% using a panel o f 4 antigens compared to 
normal controls(Robertson JFR, 2005a). In a later study from the same 
institute, sera o f breast cancer patients (PBC-97, DCIS-40) and 94 normal 
controls were tested for antibodies to a panel o f 7 antigens(Chapman et al, 
2007). Individual antibodies were raised in between 8-34% o f PBC sera and 3- 
23% in DCIS sera. Antibodies to at least one o f a panel of 6 antigens was 
identified in 64% o f PBC and 45% o f DCIS with a specificity o f 85%. One 
other study has reported on autoantibodies in patients with DCIS(Femandez- 
Madrid et al, 2004). In this study, to start with sera o f 10 patients with invasive 
breast cancer was used for immunoscreening a library o f T7 phage cDNA 
breast cancer proteins. Microarray was constructed from positive phages 
cloned with the sera. Ninety patients with breast cancer (PBC-75, DCIS-15) 
and 51 non cancer controls were used to probe the breast autoantigen 
microarray. Starting with the phage most significantly associated with cancer 
versus the non-cancer group, a 12-phage breast cancer predictor group was 
constructed. Overall, 77% o f the patients demonstrated a response to at least 
one o f the antigens. The sensitivity o f DCIS group was 60% (9/15) compared 
to 11% (8/75) in the invasive group. Annexin XI-A, one among the tumour- 
associated antigen panel suggested a possibility o f distinguishing DCIS from 
invasive breast cancer. In DCIS, 60% (9/15) o f the sera was positive for 
annexin XI-A compared to 11% (8/75) invasive breast cancers. Although the
84
above results were found to be significant, the sample size o f the DCIS group 
was small.
There are further studies which have looked into other panel o f antigens both 
in primary and advanced breast cancer. In a report by Yagihashi et al, 
prevalence o f anti-survivin and livin antibodies in sera o f 46 patients with 
breast cancer was analyzed in comparison with 10 healthy controls(Yagihashi 
A, 2005b). Anti-survivin antibodies were detected in 24% of cancer cases and 
anti-livin antibodies were detected in 33% of cancer cases. ELISA test was 
positive in 52% (24/46) of patients for one or both the antigens.
There is a further report by Zhong L et al in 87 breast cancer patients reporting 
high sensitivity and specificity with panel o f antigens (Zhong L, 2008).In this 
study, breast cancer cDNA T7 phage library was interrogated with antibodies 
in patient sera to identify aberrantly expressed tumour proteins in breast 
cancer. Six o f the phage expressed proteins were isolated and the 
corresponding antibody activities were measured by ELISA in sera o f 87 
breast cancer patients and 87 normal subjects. The results showed that 3 o f the 
phage clones reached statistical significance in determining patients from 
normal (ASB-9, SERAC1, RELT). Combing the measurements o f the three 
phage proteins in logistic regression modal achieved 80% sensitivity and 
100% specificity.
Lung cancer is another well researched area with regard to autoantibodies in 
cancer diagnosis. In a study by Chapman CJ et al from our institute, sera of 
104 lung cancers (non-small cell-82, small cell-22) and 50 controls were
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analyzed for the presence o f antibodies against a panel o f 7 antigens(Chapman 
et al, 2008). It showed a sensitivity o f 76% (79/104 patients had raised 
antibodies against at least one o f the 7 antigens) and specificity o f 92% (4/50 
patients had raised antibodies against at least one o f the 7 antigens). The 
highest level o f antibody sensitivity was seen to MUC1 peptide antigen for 
both forms of cancer (non-small cell-3 4%, small cell-3 6%), once again 
underlining the importance o f panel o f antigens in cancer diagnosis.
In another study by Yagihashi et al, sera o f 37 patients with lung cancer were 
analyzed for antibodies to livin and survivin antigens (Yagihashi A, 2005a). 
Nineteen o f the 37 lung cancer patients were positive for livin antibodies 
compared to 18 out o f 31 (58.1%) for survivin. Sera of 31 lung cancer patients 
were analyzed simultaneously for both livin and servivin, and 21 patients 
(71%) were positive for any one or both. It was noted that anti-survivin 
antibodies were found in all stages o f lung cancer, but anti-livin only in 
advanced stages. This could imply that larger expression o f livin is required 
for inducing an antibody response compared to survivin. In another study on 
survivin by Rohayem et al, sera o f 51 patients with lung cancer, 49 patients 
with colorectal cancer and 60 age and gender matched normal controls were 
analyzed for survivin and p53 antibodies(Rohayem et al, 2000). Overall 
sensitivity for both cancers was approximately 28%. In lung cancer patients, 
none o f the sera containing anti p53 antibodies recognized survivin and none 
o f the sera containing anti-survivin antibodies reacted with p53. This would 
again suggest that the prevalence o f cancer patients exhibiting antibody 
reactivity against TAAs would increase when both anti-p53 and survivin 
antibodies are determined. There are reports o f antibodies identified against
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prostate cancer specific antigens(Bradley et al, 2005; Minelli et al, 2005) 
(Huntington-interaction protein 1, protasomes, alpha-methyl-acyl-co-enzyme 
A-recemase (AMACR) and colorectal cancer specific antigens(Line et al, 
2002). However very few studies have reported on panel o f autoantibody 
assays to different antigens in diagnosis o f prostate and colorectal cancers. In a 
study by Wang et al, reported a technique which combined the use o f phage 
display library derived from prostate cancer tissue with protein microarrays for 
diagnosis o f  prostate cancer(Wang et al, 2005). Sera from prostate cancer 
patients and healthy controls were initially tested on phage peptide microarray 
developed with a phage display library derived from prostate cancer. Peptides 
with highest level o f differentiation between cancers and controls were used to 
develop specific microarrays. A panel o f 22 phage-peptide detectors were 
developed and used to analyze serum samples from 60 patients with prostate 
cancer and 68 controls. Eleven serum samples from prostate cancer and 8 from 
controls and were misclassified resulting in 81.6% sensitivity (95%CI, 0.70- 
0.90) and 88.2% specificity (95% CI-0.78 to 0.95) in discriminating between 
the groups o f prostate cancer and control group.
In a study by Ran Y et al on colorectal cancer, following immunoscreening of 
cDNA expression library prepared from colon cancer tissue, clones picked out 
by the screening were subjected to serological analysis o f a training set o f 24 
colon cancers and 24 controls(Ran et al, 2008). A combination panel o f 6 
markers which got the most satisfactory sensitivity and specificity were 
identified(Ran et al, 2008). A test course was carried out using this panel with 
an independent set o f 24 colorectal cancer sera and 24 healthy controls.
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1.2.9 Evidence for preclinical diagnosis with autoantibodies
Development o f cancer takes time, and demonstration o f autoantibodies to 
tumour antigens in sera prior to their clinical presentation could have an 
impact on outcome. That is, antibody response to carcinogen stimulus could 
form well before the tumour phenotype arises giving a lead time to cancer 
diagnosis and treatment.
Immune response to TAAs in solid tumours have been increasingly reported 
recently, and studies show antibodies to TAAs identified before symptomatic 
disease(Li et al, 2005; Robertson JFR, 2005a; Robertson JFR, 2005c). In a 
report by Robertson et al, serum taken at least 6 months before their clinical 
diagnosis o f cancer in 9 high risk subjects for breast cancer showed 
autoantibodies to a panel o f antigens (MUCl,p53, c-myc, c-erbB2) in 67% of 
the subjects(Robertson JFR, 2005a).
The lead time to tumour diagnosis ranged from 6-36 months. A further follow­
up o f a larger cohort from the same institute involving 15 high risk subjects for 
breast cancer showed autoantibodies detectable up to 4 years before 
mammographic detection o f breast cancer in 60% (9/15) o f subjects(JFR, 
2006). In another report, Yongliang Li et al looked into 103 high risk cases of 
asbestos exposure (average o f 20 year employment in asbestos related 
industries) whose follow-up blood samples were collected over an 8 year 
period(Li et al, 2005). Forty nine o f this group eventually developed cancer. 
Antibodies to p53 was found in 31 serum samples and at least one serum 
sample was positive in 13 out o f  49 (26.5%) o f those who developed cancer
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(11 lung cancer, 1 mesothelioma, 1 lymphoma) compared to 4 out of 54 who 
did not develop cancer. The average lead time to clinical diagnosis was 3.5 
years( range <1-12 years).
Autoantibodies to p53 have also been identified in cases o f heavy smokers 
before their development o f lung and other tobacco related cancers, and also in 
certain workers who have been exposed to carcinogens before their 
development o f cancer(Lubin et al, 1995; Schlichtholz et al, 1994; Trivers et 
al, 1996). Schlichtholz et al in 1994 reported the study o f 2 smokers who were 
found to have p53 antibodies in their serum(Schlichtholz et al, 1994). Follow­
up showed that one patient died rapidly from aggressive lung cancer 8 months 
later. Second patient was detected to have lung cancer 2 years later, before 
clinical manifestation o f the disease. This patient responded to treatment and 
was tumour free 4 years after treatment. Response to treatment was associated 
with disappearance o f p53 antibodies and it has not reappeared in the last 
follow-up. In a similar report by Lubin, a heavy smoker developed lung cancer 
a few years following detection o f p53 antibodies and had a cure after early 
detection and treatment(Lubin et al, 1995). In another study, serum samples o f 
92 individuals who were exposed to vinyl chloride through occupation was 
analysed for p53 antibodies (Trivers GE, 1995). Fifteen o f the above group 
developed angiosarcoma o f the liver and 5 o f  them were positive for p53 
antibodies. Two o f these patients had raised antibodies prior to diagnosis with 
one 11.3 years and the other 4 months before diagnosis. Four o f  the 77 
subjects who did not develop cancer had raised p53.
In a case control study by Trivers et al, 23 patients who developed cancer 
subsequent to chronic obstructive airway disease were analysed for p53
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antibodies(Trivers et al, 1996). Five cancer patients had raised p53, o f which 
80% (4/5) had raised p53 prior to clinical presentation with a median of 7 
months (2 lung cancers, 1 prostate cancer, 1 breast cancer). Forty four controls 
with COPD with no evidence o f cancer matched for age, gender and smoking 
habits were negative for p53. Yongliand Li et al on a later report compiled the 
results o f some o f the above mentioned studies to include 13 subjects exposed 
to carcinogens whose preclinical sera showed elevated p53 with an average 
lead time to diagnosis o f approximately 2 years(Li et al, 2005).
Another chronic inflammatory condition associated with lung cancer is 
idiopathic pulmonary fibrosis. P53 mutation has been implicated in this 
association. To test this hypothesis, Oshikawa K and his group conducted a 
case control study where serum samples o f 98 lung cancer patients, 46 patients 
with IPF (14 with lung cancer and 32 without lung cancer), 36 patients with 
pulmonary emphysema (PE) and 93 healthy controls were analysed for 
antibodies for p53 antigen(Oshikawa & Sugiyama, 2000). The sensitivity o f 
the test to p53 antibodies was significantly high in lung cancer (61.2%), IPF 
with lung cancer (57.1%) and IPF without lung cancer (53.1%) compared to 
those patients with PE (21.7%; P , 0.005) and normal controls (5%; p, 
0.00001). No significant differences were found among groups with lung 
cancer, IPF with lung cancer and IPF without lung cancer. The author suggests 
a possible mutation occurring frequently in IPF resulting in a high prevalence 
o f lung cancers.
Antibody response to survivin, a tumour associated inhibitor o f apoptosis 
protein had been identified in the sera o f 2 lung cancer patients at 12 and 18 
months before clinical manifestation o f the disease(Rohayem et al, 2000).
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Pereira-faca et al, in their case control study analysed 18 pre-diagnostic lung 
cancer sera analysed for autoantibodies 1 year prior to the development o f 
cancer(Pereira-Faca et al, 2007). Control group comprised o f 19 non cancer 
subjects matched for age, sex and time o f sample taken. Statistically 
significant greater reactivity was observed for 14-3-30 antigen (p=0.0042 ) and 
annexin 1 antigen (P= 0.0038). Reactivity against these antigens was observed 
as early as 10 months prior to diagnosis. Another report by Imani H et al on 
patients with chronic hepatitis and/or liver cirrhosis showed that 1/3"1 o f 
patients showed increasing antibody titres and novel autoantibodies at or 
before transition to hepatocellular carcinoma(Imai et al, 1993b).
Study on patients with premalignant conditions like leukoplakia and Barrett’s 
oesophagus has shown p53 antibodies in their sera suggesting its potential use 
in early diagnosis(Cawley et al, 1998; Ralhan et al, 1998). In a report by 
Ralhan R, sera o f 183 subjects (70 with oral cancer, 50 with premalignant oral 
lesions and 63 normal controls with history o f heavy consumption of tobacco) 
were analysed for p53 antibodies. Circulating p53 antibodies were observed in 
34% (24/70) o f  patients with cancer and 30% (15/50) patients with 
premalignant oral lesions(Ralhan et al, 1998). Four out o f 63 controls were 
also positive for p53 antibodies. In another report by Cawley et al, sera o f 36 
patients with Barrett’s oesophagus, 33 oesophageal cancer patients ( 23 
squamous, 10 adenocarcinoma) and 19 controls with normal oesophagus or 
with oesophagitis were analysed for p53 antibodies(Cawley et al, 1998)177. 
Four patients with Barrett’s oesophagus including one which progressed to 
adenocarcinoma had raised p53. Ten patients with cancer also had raised p53
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(8 squamous and 2 adenocarcinomas), o f which 2 had p53 prior to cancer 
diagnosis. The sensitivity and specificity o f the assay were 83.3% and 87.5% 
respectively.
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1.2.10Autoimmune disease and immune response
Autoimmune response can be systemic (rheumatoid arthritis, systemic lupus 
erythematosus) or organ specific (Graves disease, autimmune thyroiditid, type 
1 diabetes meletes). Autoantibodies are often detected many years before the 
onset o f disease(Scofield, 2004).
Some autoantibodies like antinuclear factors which are positive in diseases like 
hushimotos thyroiditis, idiopathetic thrombocytopenic purpura, dibetetes 
meletes, autoimmune haemolytic anaemia are found in n ormal subjects as 
well.
A panel o f disease specific markers may help to establish a diagnosis and to 
assess the prognosis in patients with known or suspected systemic autoimmune 
disease. These new technologies may enable screening for multiple 
autoantibodies and may further enhance the clinical usefulness o f autoantibody 
testing, making it possible to diagnose autoimmune disease in its earliest 
stages and to intervene before serious end organ damage occurs(Scofield, 
2004).
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Chapter 2. Hypothesis and project aims
In spite o f the advances in screening and treatments for cancer there continues 
to be significant mortality from cancer. Randomised controlled trials of 
screening into some of the commoner cancers like breast, colon, lung, prostate 
and cervical cancer have shown that early diagnosis has a significant impact 
on the mortality (Aberle et al, 2011; Duggan, 2012; Hardcastle et al, 1996; 
Kitchener et al, 2010; Larsson et al, 1996; Schroder et al, 2012).
Despite advances in screening for each o f the above cancers, there remains a 
significant opportunity to further improve on early detection and reduce cancer 
specific mortality. To the normal population, diagnosing cancer using a blood 
test appears a relatively simple and easy approach. The measurement o f 
autoantibodies in the peripheral blood as a means o f diagnosising early stage 
cancer has been reported previously from our institute, including lung and 
breast cancers(Chapman et al, 2007; Chapman et al, 2008) . The aim has been 
to identify raised levels o f such antibodies in individuals with cancer and 
provide preclinical blood tests as an aid to diagnosis that can be used alongside 
current imaging techniques especially in high risk population. These studies 
have compared the autoantibody signal in sera derived from both controls with 
and without cancer (Chapman et al, 2007; Chapman et al, 2008). These 
controls are wherever possible matched for risk factors and belong to a high 
risk group (Chapman et al, 2007; Chapman et al, 2008). The tumour 
associated antibody responses in the normal population is largely unknown. 
The EarlyCDT-Lung™ test (Oncimmune Ltd) measures autoantibodies 
(AABs) to six cancer-associated antigens (p53, NY-ESO-1, CAGE, GBU4-5,
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Annexinl, and SOX2) and have been reported to identify up to 40% o f lung 
cancers regardless o f grade or stage o f the disease.
We hypothesise that in subjects with no personal history o f cancer, antibody 
response to cancer related antigens alter with demographics (age, gender, and 
smoking). This thesis aims to investigate the influence o f age, gender and 
smoking on antibody responses to six cancer related antigens, in subjects with 
no previous personal history o f cancer.
As discussed previously, age is the most important risk factor for cancer, and 
we specifically analysed the AAb response with progressing age. Subjects with 
family history o f cancer are more likely to develop cancers compared to 
normal population. This being the case, it was our intention to look at the 
cancer antibody response in a subgroup o f individual who were at high risk i.e. • 
smokers and subjects with family history o f cancer. Identification of specific 
autoantibodies is well known to influence the diagnosis o f certain autoimmune 
disease and it was also our intention to investigate if  such subjects elicit a 
response to the panel o f TAAs used in our assay.
Factors investigated were
1) Relationship o f antibodies to different cancer related antigens with age
2) Influence o f gender on AAbs to TAAs in the normal population
3) Influence o f smoking on antibody response to TAAs in the Earlt CDT-lung 
panel
4) Autoantibody response to TAAs in patients with history o f autoimmune 
disease (AI)
5) Autoantibody response to cancer related antigens in subjects with family 
history (FH) o f cancer.
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Chapter 3. Materials and methods
3.1 Sample size
Graham Healey, the statistician responsible for most o f the analyses related to 
autoantibodies in previous publications from Nottingham was consulted for 
analyses o f sample size and power calculation. The process o f sample 
collection from the healthy population o f Nottingham produced a Female:Male 
ratio o f roughly 2:1, with a higher ratio at the older decades (the final overall 
ratio being 2.6:1). Given that ODs for this type o f study tend to have a 
maximum standard deviation for an antigen of around 0.15 units, and given 
also that we would like an 80% statistical power to detect a mean OD change 
o f about 0.05 units in any decade, then, based on a standard two-tailed t-test, a 
sample size o f 200 females and 100 males is adequate (estimate of power = 
76%).
3.2 Inclusion and Exclusion
Subjects with no personal history o f cancer from 18 years to 90 years were 
considered for the study.
Subjects with previous history o f hepatitis or HIV were excluded to avoid 
increased risk o f contracting the disease among staff.
3.3 Health questionnaire and consent form
Subjects invited to participate in the study were given written and verbal 
information. Opportunities to ask questions about the study were also 
provided. Once an individual decided to participate in the study, they were 
asked to fill a consent form (Appendix 1) and then a health questionnaire 
(Appendix 2). A copy o f the informed consent was given to the patients, and 
another copy o f the consent and the health questionnaire were stored in a
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secure location for record purposes (consent form in the appendix). The 
information acquired in the questionnaire included age, gender, smoking 
history, history o f benign breast disease, any autoimmune disease, exposure to 
radiation and family history o f cancer. The information collected was entered 
into a secure database which I later analysed.
3.4 Work force going to community for data collection and 
blood samples
The study was jointly supported by the University of Nottingham and one of 
it’s spinout companies, Oncimmune. Staffs from both were involved in 
organizing and managing the project. A project manager organized the events 
at different locations for optimal blood collection. These included static 
locations in the city centre, mobile locations using a bus fitted out for blood 
collection, sports centres, elderly homes, etc). Myself, and / or a fellow doctor 
were available for explaining the study and consenting the volunteers at all 
times. I was also involved also in venesection especially in some busy events 
due to the large number o f individual consenting to give blood for our 
research. At least two registered phlebotomists were available at every site to 
assist venesection. Two personnel were also available to distribute leaflets in 
public locations.
Blood sample collection was by standard venipuncture technique under aseptic 
conditions. All patients were consented and given the choice o f providing a 
minimum of 40 ml or a maximum of 58 ml for future use. All blood samples 
were allowed to stand at room temperature for one hour and centrifuged at
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1000G for 20 minutes. The serum was then removed and aliquoted into 
anonomised labeled tubes and frozen in 1 ml aliquots at -20 degree prior to 
use.
3.5 ELISA assays for the detection of autoantibodies to 
tumour associated antigens in the normal population
In this study we used the EarlyCDT®-Lung, which was first introduced in the 
clinic in May 2009 to be used as a tool to aid early detection and risk 
assessment of lung cancer in high-risk patients. It detects the presence of AAbs 
to a panel o f lung TAAs using a proprietary platform technology based on 
indirect Enzyme Linked Immunosorbent Assay. High precision robotics was 
used for all liquid handling steps to produce a highly reproducible semi- 
automated indirect enzyme-linked immunosorbant assay. Purified recombinant 
antigens were diluted to provide a semi-log titration series for each antigen 
ranging from 160 to 1.6 nM(Murray et al, 2010). Control antigens (BirA and 
NusA) were included to allow subtraction o f signal due to nonspecific binding 
to bacterial contaminants. Antigen dilutions were passively absorbed to the 
surface o f the microtitre plate wells in high phosphate buffer overnight at room 
temperature. After washing in phosphate buffered saline containing 0.1% 
Tween 20 (pH 7.6), microtitre plates were blocked with a gelatine-based 
blocking buffer. Coated plates were found to be stable for at least 48 hours 
after coating if  washed and stored at 4 degree centigrade in the presence o f 
blocking buffer. Serum samples (diluted 1 in 110 in a blocking buffer) were 
added to the plates and allowed to incubate at room temperature with shaking
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for 90 minutes. After incubation, plates were washed and horseradish 
peroxidase (HRP)-conjugated rabbit anti-human IgG was added. After a 60- 
minute incubation, the plates were washed and 3,3’,5,5’-Tetramethylbenzidine 
(TMB) was added. Following 15 minute incubation the optical density (OD) of 
each well was determined spectrophotometrically at 650 nm. Control plates to 
which antigen-specific mAbs or an anti-His tag mAb (Novagen) has been 
added in place o f serum were included to validate that the plate coating had 
been successful and antigen immunoreactivity has been maintained. These 
plates were probed with rabbit antimouse Ig-HRP.
The assays for the study were performed as semi-automated assays using 
roborts and I was involved in measurement and running o f the assays as part of 
a team required to run the robots.
3.6 Study design
The 2065 PAS samples were assayed in 11 runs over two distinct time periods 
between June 2009 and December 2009 as shown in table below. The gender 
ratio was not constant over these two sets, with the ratio for first period being 
M:F 1:11.6 and second period 1:0.4 respectively. The reason for this 
imbalance is that originally the samples had been collected for breast cancer 
screening, hence the large proportion o f females. Later there was more 
emphasis on lung cancer screening yielding increased numbers o f males.
3.7 General analysis strategy
Following the advice from Mr Graham Healey (statistician), the limit of 
quantitation in this assay is equivalent to OD=0.06 for Annexin 1 and 
OD=0.12 for all the other five antigens. Hence for the comparisons for each
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demographic factor the data values below these limits were set at the limit 
itself. This reduces the influence of imprecise extreme results on the 
interpretation.
Table 3.1: Gender by Assay Run
Gender
Assay run Male Female Unknown
23/06/09 9 191
24/06/09 12 187 1
25/06/09 13 184 3
26/06/09 25 170 5
30/06/09 17 182 1
30/06/09 13 137
01/07/09 15 134 1
10/07/09 8 118
13/10/09 103 97
11/12/09 139 70
16/12/09 212 17 1
All 566 1487 12
. . .
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Chapter 4. Results
Demographics
The study involved 2065 subjects. Male to female ratio was 1: 2.6(566:1487). 
There were approximately 200 females and 100 males in each decade except at 
the extremes o f age as shown in fig 4.1. The ratio o f  smoker versus ex­
smokers versus non-smoker was 1: 2.4: 3.8 (285:672:1096). There was a 
progressive decline in the number o f current smokers with increasing age as 
shown in fig 4.2. The proportion o f smokers and ex-smokers versus non- 
smokers remained approximately the same in both genders as shown in Fig 
4.3.
One hundred and eighty six patients (9%) had personal history o f an 
autoimmune disease and their distribution by decade and gender are shown in 
figure 4.4, 4.5 and 4.6. Diabetes mellitus and Rheumatoid arthritis were the 
commonest among the autoimmune diseases.
Almost half the patients (964) had family history o f some form of cancer as 
depicted on fig 4.7. Proportion o f females with family history o f cancer (50%) 
was comparatively higher to that o f  males (38%) as shown in fig 7.8. Figure 
4.9 shows the breakdown o f strength o f family history in each gender.
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Fig 4.1 Gender in each decade
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Fig 4.2 Smoking history in each decade
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Fig 4.3 Smoking history by Gender
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Fig 4.4 Autoimmune disease by decade
Autoimmune disease
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Fig 4.5 Different autoimmune disease by decade
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Fig 4.6 Autoimmune disease by gender
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Fig 4.7 Individuals with a reported family history of cancer categorized by
degree in each decade
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Fig 4.8 Individuals with a reported family history of cancer by gender
Fig 4.9 Individuals with a reported overall family history of cancer categorized 
by degree, gender and number
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Chapter 5. Reproducibility
Purified recombinant antigens were coated on Flacon 96 wells plates. Each 
plate had 4 repeats o f 3 antigens (p3, c-myc and NY-ESO-1) and VOL thus 
having 4 identical points on each plate. Plates were coated using electronic 
pipette in order; 160, 50 ,16 ,5  and 1.6nM. Sufficient filtered coating buffer for 
OnM was also provided. When finished, check was made to see that all wells 
o f 96 microtitre plate were correctly filled. Antigen dilutions were passively 
adsorbed to the surface o f microtitre plate wells overnight, at room temperature 
and used within one day o f coating.
After washing in phosphate buffered saline containing 0.1% Tween 20 (pH 
7.6), microtitre plates were blocked with a gelatine-based blocking buffer (200 
pl/well) using the Tecan PW -  384 plate washer “block” program. Serum 
samples (diluted manually 1 in 110 in the blocking buffer) were then added to 
the plates and allowed to incubate at room temperature with shaking for 90 
minutes. Following incubation, plates were washed and horseradish 
peroxidase (HRP)-conjugated rabbit anti-human IgG (Dako, Denmark) was 
added. Control plates to which antigen-specific monoclonal antibodies (rabbit- 
anti-mouse Ig-HRP (Dako) had been added in place o f serum were included to 
validate that the plate coating had been successful and antigen 
immunoreactivity had been maintained. After a 60-minute incubation with 
shaking, the plates were washed and 3,3’,5,5’-Tetramethylbenzidine is added 
at forty second intervals and incubate on bench for fifteen minutes, before 
reading. The optical density (OD) o f each well was determined 
spectrophotometrically at 650 nm using the Tecan Infinite Plate Reader. Data
5.1 Manual assay
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is collected in Megellan and was automatically stored as wsp file and exported
to Excel for analysis
The tables 1 and 2 represent reproducibility data o f six metastatic breast 
cancer patients who had their sera analysed using manual assays on two 
different days. Raw data were analysed using a Microsoft Excel template, and 
the mean, the standard Deviation (SD) and the coefficient o f variation (CV) 
were calculated. Within run variability less than 15% and in-between run 
variability between 15% to 25% are acceptable limits.
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Table 5.1 Reproducibility CVs and means of 3 antigens involving 3
patients with metastatic breast cancer (Cl, C5, C7)
Cl C5 C7
OD mean CVe% CVb% mean CVe% CVb% mean CVe% CVb%
p53 50 0.335 38.07 25.32 0.115 19.98 38.12 0.1915 37.64 7.75
160 0.2545 68.13 16.39 0.1285 49.02 33.56 0.2825 11.95 29.78
c-myc 50 0.3765 27.13 7.32 0.251 6.89 37.74 0.5535 6.53 22.86
160 0.5335 41.98 15.24 0.353 12.01 28.44 0.976 2.73 22.31
NY-ESO-1 50 0.4505 18.44 13.65 0.1405 23.04 27.68 0.5905 .341 42.74
160 0.5815 19.57 11.06 0.215 0.43 36.83 0.843 5.61 37.91
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Table 5.2 Reproducibility CVs and means of 3 antigens involving 3
patients with metastatic breast cancer (C8, C9, C ll)
C8 C9 C l l
OD mean CVe% CVb% mean CVe% CVb% mean CVe% CVb%
P53 50 0.08 27.23 10.60 0.1665 43.90 18.26 0.267 7.08 14.30
160 0.092 62.27 29.20 0.604 52.34 114.26 0.263 1.21 36.02
c-myc 50 0.1275 4.91 12.75 0.1525 16.48 0.463 0.288 7.69 1.96
160 0.18 4.75 15.71 0.3935 9.99 82.48 0.3565 2.81 8.52
NY-ESO-1 50 0.1085 38.44 9.77 0.9265 5.19 27.09 0.3885 26.02 7.46
160 0.1105 50.40 1.91 0.9875 2.19 27.85 0.5115 5.68 20.59
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The population antibody study involved 2065 samples assayed in 11 runs and 
each run on a different day. Approximately 180-200 samples could be run in 
one day. Each o f the 11 runs had 3 same pleural fluid assays (PL-164, PL-186, 
PL-192) as controls with two repeats per runs in each plate. This allowed a 
straightforward between-run reproducibility analysis to be carried out, with the 
two replicates representing the within-run (ie within-plate) variability. For 
each control, antigen and concentration, between-run (Vb) and within-run 
(Ve) variance components were estimated using analysis o f variance (SAS® 
Proc Varcomp). Results were expressed as CVs (coefficients o f variation) for 
a single replicate where:
5.2 Semi-automated assay reproducibility
Within-run CV = 100V(Ve)/mean 
Between-run CV = 100V(Vb+Ve)/mean
For the statistical comparisons, analysis o f variance was generally used for OD 
data o f antigen concentration (50nM and 160nM).
Results
Pleural fluid PL164, PL186 and PL192 had 11 runs with 2 repeats per run in 
each plate. Mean optical density o f antibodies to each o f 6 antigens in 2 
concentrations (50 and 160) was looked into as shown in Table 5.1. The lower 
the optical density reading, the higher the coefficient o f  variation. Small
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absolute difference can result in large CV’s. The lower limit o f quantitation 
for this assay is approximately OD=0.12. For cases where mean OD>0.12 the 
within-run CV (CVe) ranged from 3% to 14% and the between-run CV (CVb) 
from 5% to 26%. Cv’s cannot be calculated for negative means. Further 
detailed summary o f CV’s by mean OD is given in table 5.2. Figure below 
shows clearly the reproducibility o f the assay whenever the OD mean is above 
the limit o f quantitation (0.12) , with the CVs shooting off to infinity below 
mean OD = 0.01.
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Table5.3- Reproducibility CVs and means by Control and Antigen
PL-164 PL-186 PL-192
OD mean CVe% CVb% mean CVe% CVb% mean CVe% CVb%
p53 50 0.09 15 22 1.82 5 5 0.07 24 69
160 0.21 12 13 1.82 5 6 0.21 10 15
SOX2 50 -0.03 • • 0.04 40 47 0.02 88 184
160 -0.11 • • 0.04 50 64 -0.03 • •
CAGE 50 0.07 23 26 1.10 4 13 0.05 27 113
160 0.17 14 25 1.39 3 8 0.15 14 25
NY-ESO-1 50 0.09 13 40 0.01 275 275 0.00 482 2097
160 0.34 8 26 0.01 84 102 0.05 29 47
GBU4-5 50 0.09 13 35 0.01 227 227 0.02 45 208
160 0.30 6 16 0.02 72 96 0.12 14 18
Annexin 1 50 0.02 48 48 0.01 185 185 0.00 509 2238
160 0.07 18 26 0.02 79 95 0.05 46 50
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Table5.4- Summary of CVs by mean OD
CVe% CVb%
Mean OD 0.0-0.1 0.1-0.3 0.3-2.0 0.0-0.1 0.1-0.3 0.3-2.0
p53 15-24 10-12 5 22-69 13-15 5-6
SOX2 40-88 47-184
CAGE 23-27 14 3-4 26-113 25 8-13
NY-ESO-1 13-482 8 40-2097 26
GBU4-5 13-227 6-14 35-208 16-18
Annexin 1 18-509 26-2238
ALL 13-509 6-14 3-8 22-2238 13-25 5-26
Figure 5.1: Between-run CV (CVb) vs OD mean reproducibility of the 
assay whenever the OD mean is above the limit of quantitation (0.12).
P l o t  o f  h « t w « * n - n in  C V  v i  m oan OD
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Chapter 6. Relationship of antibodies to different 
cancer related antigens with Age
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To analyse the impact o f age on antibodies to cancer related antigens, we 
classified patients into different decades and analysed i f  there was a difference 
between different groups
6.1 Relationship of antibodies to cancer related antigen p53 
with age
We used the test for trend, Jonckheere-Terpstra which is a non parametric 
method for showing trend. It was used to analyse if  there was a trend with 
changing decade. The figure 6.1 shows that there is a progressive increase in 
the median optical density o f  antibodies to p53 antigen in all subjects with 
progressing decades. In Table 6.1, overall median OD o f all samples was taken 
into account. For each decade, it shows the number o f subjects with values 
above and below this median. You see that as the age increases the proportion 
o f subjects with values above this overall median also increases. In short, with 
progressing decade the proportion o f subjects with optical density above the 
median value also increased.
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Fig 6.1 Box and whisker plot showing progressive rise in optical density of
antibodies to p53 antigen with progressing decade
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Table 6.1 showing rise in subjects with optical densities o f antibodies to p53
antigen above the overall median with progressing decade
Number of subjects in each 
decade (%)
18-29 yrs 30-39 yrs 40-49 vrs 50-59 yrs 60-69 yrs >70 yrs
od160 > Median 
<= Median
115(39) 
177 (61)
140 (46) 
163 (54)
165 (46) 
191 (54)
177 (51) 
170 (49)
248(54) 
209 (46)
178 (61) 
113(39)
Median OD- 0.194 
P value = 0.0001
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Figure 6.2 also shows a progressive increase in the median optical density of 
antibodies to cage antigens with increasing decade, and the table 6.2 also 
suggests that as the decade increases the proportion of subjects with optical 
density above the overall median value also increases.
6.2 Relationship of antibodies to cancer related antigen CAGE
with age
Fig 6.2 Box and whisker plot showing progressive rise in optical density of 
antibodies to CAGE antigen with progressing decade
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Table 6.2 showing rise in optical densities o f antibodies to CAGE antigen
above the median with progressing decade
Number of subjects in each 
decade(%)
18-29 yrs 30-39 yrs 40-49 yrs 50-59 yrs 60-69 yrs >70 yrs
od160 > Median 114(39) 142 (47) 168 (47) 199 (57) 240 (53) 159(55)
<= Median 178 (61) 161 (53) 188 (53) 148 (43) 217(47) 132 (45)
Median OD- 0.150 
P= 0.0001
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Figure 6.3 also shows a trend towards increase in the median optical density 
of antibodies to NY-ESO-1 antigens with increasing decade, and similarly to 
previous antigens showing a progressive increase in number of subjects with 
higher optical density than the median value with progressing decade as shown 
in table 6.3, although not that pronounced as with previous two antigens.
6.3 Relationship of antibodies to cancer related antigen NY-
ESO-1 with age
Fig 6.3 Box and whisker plot showing progressive rise in optical density of 
antibodies to NY-ESO antigen with progressing decade
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Table 6.3 showing rise in optical densities o f antibodies to NY-ESO antigen
above the median with progressing decade
Number o f subjects in each 
decade(%)
18-29 yrs 30-39 yrs 40-49 yrs 50-59 yrs 60-69 yrs >70 yrs
od160 > Median 110(38) 102 (34) 131 (37) 161 (46%) 193 (42) 136 (47)
<= Median 182 (62) 201 (66) 225 (63) 186 (54) 264 (48) 155 (53)
Median OD-O.12 
P = 0 .0 0 0 1
6.4 Relationship of antibodies to cancer related antigen GBU 
4-5 with age
Figure 6.4 also shows a similar finding to the previously described antigens 
and shows a progressive increase in the median optical density o f antibodies to 
GBU 4-5 antigens with increasing decade, and there was a progressive 
increase in number o f subjects with higher optical density than the median 
value with progressing decade as shown in Table 6.4. These have been found 
to be statistically significant with a P= 0.0001
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Fig 6.4 Box and whisker plot 
antibodies to GBU 4-5 antigen
showing progressive rise in optical density of
with progressing decade
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Table 6.4 showing rise in subjects with optical densities o f antibodies to GBU
4-5 antigen above the median with progressing decade
Number o f subjects in each 
decade(%)
18-28 yrs 30-39 yrs 40-49 yrs 50-59 yrs 60-69 yrs >70 yrs
od 160 > Median 127 (43) 124 (41) 164(46) 187 (54) 246 (54) 174(60)
<= Median 165 (57) 179 (59) 192 (54) 160 (46) 211 (46) 117(40)
Median OD-0.20
P= 0.0001
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Both Annexin 1 and Sox-2 did not have any influence with age as shown in 
respective graphs 6.5 & 6.6 and tables 6.5. & 6.6
Fig 6.5 Box and whisker plot showing no significant difference in mean 
optical density of antibodies to Annexin 1 antigen with progressing decade
6.5 Relationship of antibodies to cancer related antigen
Annexin 1 with age
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Table 6.5 showing no significant difference in optical densities o f  antibodies
to Annexin 1 antigen above and below the overall median with progressing
decade
Number o f subjects in each 
d ecade (%)
18-29yrs 30-39 yrs 40-49 yrs 50-59 yrs 60-69 yrs >70 yrs
od 160 > Median 137 (47) 139 (46) 158 (44) 155 (45) 207 (45) 141 (48)
<= Median 155 (53) 164 (54) 198 (56) 192 (55) 250 (55) 150 (52)
Median OD-0.06 
P=0.467
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Fig 6.6 Box and whisker plot showing no significant difference in mean 
optical density of antibodies to SOX2 antigen with progressing decade
6.6 Relationship of antibodies to cancer related antigen SOX2
with age
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Table 6.6 showing no significant difference in optical densities o f  antibodies
to SOX2 antigen above and below the overall median with progressing decade
Number of subjects in each 
decade (%)
18-29 yrs 30-39 yrs 40-49 yrs 50-59 yrs 60-69 yrs >70 yrs
od160 > Median 17(6) 9 (3 ) 10(3 ) 19(6) 28(6) 15(5)
<= Median 275 (94) 294 (97) 346 (97) 328 (94) 429 (94) 276 (95)
Median OD- 0.12 
P=0.230
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6.7 Discussion
Our study involved 2065 subjects with approximately equal distribution of 
females and males in each decade. The study shows that there is a progressive 
increase in the median optical density for most antibodies to cancer related 
antigens with progressing decades. The proportion o f subjects in each decade 
o f life with optical density values o f AAbs above the overall median compared 
to those below the median increased with each decade for p53, CAGE, NY- 
ESO-1 and GBU4-5 and it was statistically significant for these antigens. The 
incidence o f cancer also increased with age and increased response o f 
antibodies to these antigens with age could be a reflection o f cancer becoming 
more common with age. It is also possible that increasing age itself has an 
influence on the level o f auto antibodies to some o f the tumour associated 
antigens as could be the case with benign autoimmune disease and it could be 
a true reflection o f the level in each decade. It has been shown that incidence 
o f benign autoimmune disease increases with age(Morganti et al, 2005) and 
levels o f immunoglobulins G also increases with age(Rink & Seyfarth, 1997).
We have seen that older age groups have higher autoantibody response to 
cancer related antigens. There are no studies in the present literature which 
have followed up these older age groups with higher autoantibody response to 
see i f  they develop cancer. This would be a future project to follow-up these 
selected group o f  subjects with higher OD values.
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With regard to Annesxin 1 and SOX-2, the autoantibody response did not alter 
with age. It is probable that the response against these antigens (Annexin 1 and 
SOX2) is truly cancer specific and age has little influence on its levels.
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Chapter 7. Influence of gender on auto antibodies 
to cancer related antigens in a normal population
138
Between females and males there was no difference in autoantibody response 
to p53 antigen as shown in figure 7.1. Unpaired t-test comparing males and 
females shows that there is no difference in the mean optical densities between 
males and females with regard to p53 antigen (P=0.06).
7.1 Autoantibody response to p53 antigen between genders
Fig 7.1 Showing no significant difference in mean optical densities of 
antibodies to p53 antigen between genders
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When we looked into the autoantibody response to CAGE, the mean optical 
density was significantly higher in males with a P value of 0.0001 as shown in 
figure 7.2. To eliminate the effects of smoking and age, 1:1 matching was 
done for sex, smoking history and age (+/- 3 years). There were 528 subjects 
in each group. Even after matching, the analysis showed a statistically 
significant higher mean optical density in males (Mann-Whitney P=0.0001) as 
shown in figure7.3.
7.2 Autoantibody response to CAGE antigen between genders
Fig 7.2 Showing significant difference in mean optical densities of antibodies 
to CAGE antigen between genders
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Fig 7.3 Showing significant difference in mean optical densities of antibodies 
to CAGE antigen between genders after l:l matching for age, gender and 
smoking.
Gender
I 4 l
Table 7.1 Showing significant difference in mean optical densities above and 
below the overall median o f antibodies to CAGE antigen between genders 
after 1:1 matching for age, gender and smoking.
Gender
Male (%) Female (%)
OD160 »M edian 298 (56) 229 (43)
<= Median 230 (44) 299 (57)
Median OD- 0.157 
P=0.0001
One hypothesis for the gender difference in CAGE is due to the imbalance in 
gender across assay runs. In fact the means for CAGE were very similar in 
period A as shown in table 7.2, but in period B there was an increase in males 
with a difference in mean optical densities between genders. This could 
suggest that the difference for CAGE is not a universal effect but may only 
apply to certain sub-groups.
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Table7.2- OD mean for gender by assay period
Period Male Female Total
A 0.184 0.186 0.186
(n= 112) (n=1303) (n=1415)
B 0.220 0.183 0.209
(n=454) (n=184) (n=639)
566 1487 2065
Following the advice from M r Graham Healey (statistician) analysis o f 
variance was used to adjust the gender means for the imbalance in gender 
frequency and means across individual runs for CAGE. This specific analysis 
was done with the help o f  Mr Healey and the explanation given is as follows. 
In the statistical analysis module SAS/Stat, in the commercial data analysis 
software SAS®, the analysis o f  variance command Proc GLM was applied 
with and without a term for assay run. Omitting the run term gives the 
unadjusted gender comparison between ignoring run. Including the run term 
removes the between-run variation from the error variance and also corrects 
the gender means for the deviation o f the individual run means from the 
overall average over runs. It can be seen in the table below that after adjusting 
for the imbalance in gender frequency and means for individual runs for 
CAGE, it has largely removed the gender difference, suggesting that the 
observed gender difference for CAGE might be a technical artefact.
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Table7.3 OD means for Cage, unadjusted and adjusted for run differences
Unadjusted Adjusted
Male Female /»-value Male Female /»-value
Cage 0.213 0.186 <0.0001 0.195 0.190 0.56
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Unpaired t-test comparing males and females shows that there is no difference 
in the mean optical densities between males and females with regard to 
antibodies to NY-ESO antigen (P=0.138). Figure 7.4 shows between females 
and males there was no difference in autoantibody response to NY-ESO-1 
antigen.
Fig 7.4 showing no difference between the mean optical densities of 
antibodies to NY-ESO antigen between genders
7.3 Autoantibody response to NY-ESO-1 antigen between two
2 genders
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Unpaired t-test comparing males and females shows that there is no difference 
in the mean optical densities between males and females with regard to GBU 
4-5 antigen (P=0.721). Figure 7.5 shows between females and males there 
was no difference in autoantibody response to GBU 4-5 antigen.
7.4 Autoantibody response to GBU 4-5 antigen between
genders
Fig 7.5 showing no difference between the mean optical densities of 
antibodies to GBU 4-5 antigen between genders
gender
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Figure 7.6 shows no difference between the mean optical densities of 
antibodies to Annexin 1 antigen between genders. Unpaired t-test comparing 
males and females shows that there is no difference in the mean optical 
densities between males and females with regard to Annexin 1 antigen 
(P=0.412).
7.5 Autoantibody response to Annexin-1 antigen between
genders
Fig 7.6 showing no difference between the mean optical densities of 
antibodies to Annexin 1 antigen between genders
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Figure 7.7 shows no difference between the mean optical densities of 
antibodies to SOX2 antigen between genders. Unpaired t-test comparing males 
and females shows that there is no difference in the mean optical densities 
between males and females with regard to SOX 2 antigen (P=0.196).
Fig 7.7 showing no difference between the mean optical densities of 
antibodies to SOX-2 antigen between genders
7.6 Autoantibody response to SOX2 antigen between genders
OJD T
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7.7 D isc u ss io n
Male to female ratio o f subjects in our study was 1: 2.6(566:1487). There were 
approximately 200 females and 100 males in each decade except at the 
extremes o f age. When we looked into the autoantibody response, except for 
CAGE, there was no significant difference in mean optical densities between 
males and females. As for CAGE there was significant difference between the 
groups even after eliminating the effects o f smoking and age by 1:1 matching 
for sex, smoking history and age (+/- 3 years). Over 500 subjects in each 
gender were matched for age (+/- 3 years) and smoking history. However, this 
also showed a significant difference for autoantibody response to CAGE 
antigen. CAGE is a cancer testes antigen and in normal individuals its 
expression is largely restricted to testes(Alsheimer et al, 2005). It is possible 
that this antigen levels are inherently elevated in males, and with genetic 
changes with age they are no longer recognised as self and thus producing an 
elevated antibody response. However, if  the above hypothesis is true, this 
should be the case with NY-ESO as well as it is also a cancer testes antigen.
The tests for males and female were run no differently as they were all mixed 
together and subgroup analysis being done after all the runs have been 
completed. There is the possibility o f variation between runs on different days, 
although this should apply to all antigens with no exception to CAGE AAb 
response. It is probable that when making so many exploratory analyses, some 
of the P values less than 0.05 will turn out to be spurious. Since there is no 
really good biological hypothesis to explain this result, it might be worthwhile 
repeating this on a different sample set if  possible.
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Chapter 8. Influence of smoking on antibody 
response to cancer related antigens
150
Autoantibody response to cancer related antigens p53 was low in smokers as 
shown in fig 8.1. The mean autoantibody response was more in the ex-smoker 
group compared to the other two groups. Kruskal-Wallis test was used to see if  
there was any difference between the groups and the test was found to be 
statistically significant with a P value less than 0.0001.
To eliminate the possible effect o f age and gender, matched analysis was again 
done to see i f  there is a difference in the three smoking history groups and the 
trend remained the same despite matching as shown in figure 8.2. and was 
statistically significant with a p value equal to 0.0001. Median optical densities 
in the Ex-smoker group was significantly higher as shown in table 8.1.
8.1 Autoantibody response to p53 antigen in smokers ex­
smokers and non-smokers
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F ig  8 .1  Showing higher autoantibody response to p53 antigen in ex-smokers
compared to the other two groups.
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Fig 8.2 Autoantibody response to p53 antigen in smoking groups matched for
age
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Table 8.1 showing number o f subjects above and below the median optical 
density o f antibody to P53 antigen in different age matched and sex matched 
smoking groups
Smokinq history (%)
smoker Ex-smoker Non-smoker
od160 »M edian 74 (45) 190 (59) 243 (43)
<= Median 90 (55) 134(41) 325 (57)
Median OD-0.20 
P=0.0001
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Autoantibody response to cancer related antigens CAGE was also low in 
smokers as shown in figure 8.3. The autoantibody response was more in the 
ex-smoker group compared to the other two groups. Kruskal-Wallis test was 
used to see if  there was any difference between the groups and the test was 
found to be statistically significant with a P value < 0.004. Matched analysis 
was again done, and the study showed no significant difference between the 
groups when subjects were age and sex matched (P= 0.058) as shown in figure 
8.4. Table 8.2 also shows the subjects in different groups above and below the 
median.
8.2 Autoantibody response to CAGE antigen in smokers ex­
smokers and non-smokers
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F ig  8.3 Showing higher autoantibody response to CAGE antigen in ex­
smokers compared to the other two groups.
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Fig 8.4 showing autoantibody response to cage in smoking groups matched for 
age and gender
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Table 8.2 Showing number o f subjects above and below the median optical 
density o f antibody to CAGE antigen in different age matched and sex 
matched smoking groups
Smokinq history (%)
smoker Ex-smoker Non-smoker
od160 > Median 69 (42) 170 (52) 261 (46)
<= Median 95 (58) 154 (48) 307(54)
Median OD-O.16 
P=0.058
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Autoantibody response to cancer related antigens NY-ESO-1 was universal in 
all the three groups. Kruskal-Wallis test used to make comparison between 
groups and it did not show any statistical difference between the groups (P 
value = 0.05) as shown in figure 8.5. Age matched comparisons were also 
made as shown in fig 8.6 and this also did not reach statistical significance
(p = 0 .1 2 ) .
8.3 Autoantibody response to NY-ESO-1 antigen in smokers,
ex-smokers and non-smokers
Fig 8.5 Showing no significant difference in the autoantibody response to NY- 
ESO-1 antigen in smokers, ex-smokers and non-smokers
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Figure 8.6 Autoantibody response to NY-ESO-1 in smoking groups matched 
for age
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Table 8.3 showing number o f subjects above and below the median optical 
density o f antibody to NY-ESO antigen in different age matched and sex 
matched smoking groups
Smoking history (%
smoker Ex-smoker Non-smoker
od160 > Median 
<= Median
50 (30) 
114(70)
125 (36) 
199 (64)
219(39) 
349 (61)
Median-0.12
P=0.145
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As with the first 2 antigens, autoantibody response to cancer related antigen 
GBU 4-5 was also low in smokers. The autoantibody response was also more 
in the ex-smoker group compared to the other two groups as shown in figure 
8.7. Kruskal-Wallis test was used to see i f  there was any difference between 
the groups and the test was found to be statistically significant with a P value 
less than 0.0007.
Age matched analysis was again done to see if  there is a difference in the three 
smoking history groups and the trend remained the same despite matching as 
shown in fig. 8.8 and was statistically significant (P=0.001).
8.4 Autoantibody response to GBU4-5 antigen in smokers, ex­
smokers, and non-smokers
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F ig  8.7 Showing higher autoantibody response to GBU 4-5 antigen in ex­
smokers compared to the other two groups.
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Fig 8.8 Autoantibody response to GBU 4-5 antigen in smoking groups 
matched for age
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Table 8.4 showing number o f subjects above and below the median optical 
density o f antibody to GBU 4-5 antigen in different age matched and sex 
matched smoking groups
Smoking history (%)
smoker Ex-smoker Non-smoker
od160 > Median 67 (41) 172(53) 283 (49)
<= Median 97 (59) 152 (47) 285 (51)
Median OD-O.21 
P-0.037
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The autoantibody response to cancer related antigen Annexin 1 was low across 
the all three groups. Kruskal-Wallis test however showed a significant 
difference between groups (P=0.004) as shown in figure 8.9. Age and sex 
matched analysis also maintained the difference between the three groups with 
a P value o f 0.003 as shown in figure 8.10
8.5 Autoantibody response to Annexin 1 antigen in smokers,
ex-smokers, and non-smokers
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F ig  8.9 Showing low autoantibody response to Annexin 1 antigen across all
three groups.
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Fig 8.10 Autoantibody response to Annexin 1 antigen in smoking groups 
matched for age
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Table 8.5 showing number o f subjects above and below the median optical 
density o f antibody to Annexin 1 antigen in different age matched and sex 
matched smoking groups
Smokinq history (%)
smoker Ex-smoker Non-smoker
od160 > Median 65 (40) 164 (51) 217(38)
<= Median 99 (60) 160 (49) 351 (68)
Median OD-0.06 
P=0.001
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Autoantibody response to cancer related antigens SOX 2 was also low across 
the all three groups with the least response in the smoking group as shown in 
figure 8.11. Kruskal-Wallis test was used to see if  there was any difference 
between the groups, and the test was found to be statistically significant with a 
P value less than 0.042
Age matched analysis was again done to see if  there is a difference in the three 
smoking history groups and this did not show any difference between the three 
groups ( p=0.308) as shown in figure 8.12.
8.6 Autoantibody response to SOX-2 antigen in smokers, ex­
smokers, and non-smokers
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F ig  8 .1 1  Showing low autoantibody response to SOX-2 antigen across all
three groups.
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F ig  8 .1 2  Autoantibody response to SOX-2 antigen in smoking groups matched
for age
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Table 8.6 Showing number o f subjects above and below the median optical 
density o f  antibody to SOX-2 antigen in different age matched and sex 
matched smoking groups
Smoking history (%)
smoker Ex-smoker Non-smoker
> Median
od 160
<= Median
7 (4 ) 
157 (96)
13(4) 
311(96)
2 1 (4 ) 
547 (96)
Median OD-O.12 
P=0.936
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8.7 Discussion
Autoantibody response to p53, CAGE, GBU 4-5 and Annexin 1 and SOX2 
were high in ex-smokers compared to smokers and non smokers and this 
reached statistical significance when comparisons between the mean optical 
densities between the groups were made. When age matched analysis were 
done, the differences were statistically significant for p53, GBU 4-5 and 
Annexin 1.
The autoantibody response was comparatively low in smokers compared to ex­
smokers and it is probable that smoking produces a suppression o f immune 
response (Amson et al, 2010; Subramanyam, 2011; Wu et al, 2011) leading to 
their relatively low response. The rise in autoantibody response was more in 
the ex-smoker group compared to the other two groups in all the antigens 
except for NY-ESO 1, suggesting the possibility o f  rebound effect when 
smoking is stopped. Why this was not the case with NY-ESO 1 is not clear. To 
explore further the "rebound” hypothesis which proposes that on cessation 
after a period o f smoking, AAb levels rise to a higher level than during periods 
o f smoking or non-smoking, the year o f quitting for ex-smokers were extracted 
from the database. Any association between AAb levels and time lapse since 
quitting might provide support to this hypothesis. The table below summarises 
the results by decades o f year quitting and very little difference was seen for 
most antigens back to 1970, but decades before that there was an observed 
increase in the mean AAb level for all antigens except SOX2.
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Table8.7 - M ean OD by year of smoking cessation for Ex-smokers
Year quit n P53 SOX2 Cage NY-ESO-1 GBU4-5 Annexin 1
1950-69 47 0.288 0.127 0.238 0.177 0.287 0.116
1970-79 124 0.237 0.127 0.178 0.156 0.250 0.084
1980-89 151 0.252 0.133 0.197 0.159 0.246 0.086
1990-99 104 0.251 0.130 0.221 0.162 0.239 0.092
2000-09 209 0.246 0.130 0.199 0.159 0.254 0.086
All 635 0.250 0.130 0.201 0.160 0.251 0.089
p-val (KW) 0.08 0.60 <0.001 0.46 0.49 0.04
p-val (JT)
However, the difference was not statistically significant. As you can see many 
o f the ex-smokes had stopped smoking a number o f years prior to the blood 
sample date and thus it is not clear whether this rebound effect is a true 
phenomenon. Further work would be required to establish such an effect.
P53 is one o f the well known antigens which has been linked to cancers 
closely associated with smoking. However previous studies have shown that 
although antibodies to p53 antigen is frequently elevated in patients with 
cancers which are closely linked to smoking, it has failed to show significantly 
elevated levels in smokers without cancer(Dilek Dincol, 2001; Sangrajrang et 
al, 2003)
175
Chapter 9. Autoantibody response to cancer related
antigens in patients with history of autoimmune disease
176
Nine percent of the subjects had personal history of autoimmune disease. 
Comparisons were made between those with autoimmune disease and those 
without the disease. The study did not show any statistically significant 
difference in response to all six cancer related antigens when comparisons 
were made with those with and without personal history of autoimmune 
disease as shown in respective figures.
Fig 9.1 showing no difference in antibody response to p53 antigen between the 
two groups
9.1 Autoantibody response to p53 in those patients with and
without autoimmune disease
Mann Whitney test 
P value- 0.5337
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9.2 Autoantibody response to CAGE in those patients with
and without autoimmune disease
Fig 9.2 showing no difference in antibody response to CAGE antigen between 
the two groups
Mann Whitney test 
P value- 0.784
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9.3 Autoantibody response to NY-ESO-1 in those patients
with and without autoimmune disease
Fig 9.3 showing no difference in antibody response to NY-ESO antigen 
between the two groups
Mann Whitney test 
P value 0.5705
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9.4 Autoantibody response to GBU 4-5 in those patients with
and without autoimmune disease
Fig 9.4 showing no difference in antibody response to GBU 4-5 antigen 
between the two groups
Mann Whitney test
P value- 0.7638
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9.5 Autoantibody response to Annexin-1 in those patients with
and without autoimmune disease
Fig 9.5 showing no difference in antibody response to Annexin 1 antigen 
between the two groups
Mann Whitney test
P value- 0.1152
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Fig 9.6 showing no difference in antibody response to SOX2 antigen between 
the two groups
Mann Whitney test
P value- 0.6454
9.6 Autoantibody response to SOX2 in those patients with
and without autoimmune disease
1J5n
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9.7 Discussion
Autoimmune diseases (AI) are prevalent in our society and some o f them have 
links to cancer (Aggarwal et al, 2012; Orozco et al, 2012; Segal et al, 1985). 
However, it is not known if  the autoantibody response to TAAs in subjects 
with AI differs to that o f the normal population.
In our study, 186 subjects (9%) had personal history o f an AI. Diabetes 
mellitus and Rheumatoid arthritis were the commonest among the AI.
Mean optical densities o f all six cancer related antigens were analysed between 
the two groups and this did not show any statistical difference (p53; P= 0.533 
CAGE; P= 0.784, NY-ESO; P= 0.570, GBU 4-5; P= 0.763, Annexin 1; P= 
0.115, SOX 2; P= 0.645).
Our hypothesis was that the autoantibody response to tumour associated 
antigens is specific and we did not expect an increased autoantibody response 
to tumour associated antigens in subjects with autoimmune disease. Studies 
have shown that tumour associated antigens are cancer specific (Lubin et al,
1995; Pedersen et al, 2011). Previous study from our institute has looked into 
the specificity o f  the human immune response against the six recombinant 
tumour-associated antigens measured in the £ar/yCDT™ -Lung test(A Murray, 
2011). The six recombinant antigens (p53, SOX2, CAGE, NY-ESO-1, GBU4- 
5 and Annexin 1) were analysed by SDS-PAGE and Western Blotting. The 
blots were probed both with antigen specific monoclonal antibodies and 
positive sera. Enzyme Linked Immunosorbant Assays (ELISA) were 
performed in which positive sera were pre-incubated with a range o f different 
proteins before being allowed to react with the test antigens in order to show
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antigen-specific inhibition o f binding o f these sera. Inhibition ELIS As using 
positive sera showed that binding to each antigen could be inhibited by the 
antigen itself but not by bovine serum albumin, VOL (a recombinant antigen 
produced and purified in the same way as the £ar/yCDT™ -Lung antigens or 
by one o f the other cancer antigens in the panel.
Our present results also showed no significant increased response to cancer 
related antigens in these subjects with autoimmune disease compared to those 
without the disease. The implication o f this result would be that, patients with 
autoimmune disease could be tested for autoantibodies to tumour associated 
antigens and the results should be as meaningful as to someone without 
autoimmune disease.
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Chapter 10. Autoantibody response to cancer related
antigens in subjects with family history of cancer
185
Approximately 50% of subjects had a relative with history of cancer. 
Comparisons were made between those with and those without family history 
of cancer. The study did not show any statistically significant difference in 
response to all six cancer related antigens when comparisons were made with 
those with and without family history of cancer as shown in respective figures.
10.1 Autoantibody response to p53 antigen in those subjects
with and without family history of cancer
Fig 10.1 showing no difference in antibody response to p53 antigen between 
the two groups
Mann Whitney test 
P value- 0.4741
$
186
10.2 Autoantibody response to CAGE in those subjects with 
and without family history of cancer 
Fig 10.2 showing no difference in antibody response to CAGE antigen 
between the two groups
Mann Whitney test 
P value- 0.9814
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Fig 10.3 showing no difference in antibody response to NY-ESO-1 antigen 
between the two groups
Mann Whitney test 
P value- 0.1047
10.3 Autoantibody response to NY-ESO-1 in those subjects
with and without family history of cancer
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10.4 Autoantibody response to GBU 4-5 in those subjects with 
and without family history of cancer 
Fig 10.4 showing no difference in antibody response to GBU 4-5 antigens 
between the two groups
Mann Whitney test 
P value- 0.4213
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10.5 Autoantibody response to Annexin 1 in those subjects with 
and without family history of cancer 
Fig 10.5 showing no difference in antibody response to Annexin 1 antigen 
between the two groups
Mann Whitney test
P value- 0.4684
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Fig 10.6 showing no difference in antibody response OX-2 antigen between 
the two groups
10.6 Autoantibody response to SOX2 antigen in those subjects
with and without family history of cancer
Mann Whitney test 
P value- 0.7192
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10.7 Discussion
Family history is one o f the strong risk factors for many o f the common 
cancers. Approximately one in two o f our subjects in our study had first or 
second degree relative with cancer. When comparisons were made with regard 
to antibody response in the two groups with and without family history of 
cancer, it failed to reach statistical significance. Mean optical densities o f  
antibodies to all six cancer related antigens were analysed between the two 
groups and this did not show any statistical difference (p53; P= 0 4741 
CAGE; P= 0.9814, NY-ESO; P= 0.1047, GBU 4-5; P= 0.4213, Annexin 1; P= 
0.4684, SOX2; P= 0.7192).
In our study we looked into subjects across all decades o f  life and not simply 
the older decades where the cancers are more common, as we wanted to 
address whether family history per se was linked to the presence o f 
autoantibodies against tumour associated antigens as opposed to someone with 
a family history is actually developing cancer. What these data show is that on 
a population basis, simply having family history o f cancer doesn’t make you 
more likely to have autoantibodies to tumour associated antigens. If  a subject 
show an increased autoantibody response to these tumour associated antigens, 
it is more likely that this is due to them developing cancer themselves rather 
than being linked to their family history. This is in line with the hypothesis that 
these elevated autoantibodies reflect the induction o f  carcinogenesis. However, 
in subjects with specific mutation like BRCA1 or 2, you may get antibodies 
directly linked to the mutation. There is no data available at present to suggest 
that individuals with these mutations make antibodies to a protein associated 
with genetic mutation, and is probably because they see these proteins as self.
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In these individuals with high risk o f  developing cancer, you may have to look 
for autoantibodies to other tumour associated antigens.
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Chapter 11. Conclusion and future direction
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Our work has added new findings in the field o f autoantibodies i.e. their 
prevalence in normal population and in association with various demographic 
risk factors. My thesis is different from other published work in that, the 
population we targeted were community based and not subjects attending the 
hospital i.e. patients. Previous studies on autoantibodies have limitations due 
to their selection o f controls or the lack o f such controls. Often studies use 
limited number o f normal individuals without cancer as controls which may 
not be representative o f the normal population as a whole. The controls in 
some studies are often younger and relatively healthy and some studies report 
using ‘blood donors’ as controls and all these subject groups do not represent a 
normal community population.
This unique community based work looks into the spectrum of autoantibody 
response in the normal population and looks into different demographic 
subgroups within the community. In our study there was a progressive 
increase in the median optical density o f antibodies to tumour associated 
antigens with progressing decades. The proportion o f subjects in each decade 
o f life with optical density values above the overall median compared to those 
below the median increased with progressing decade for p53, CAGE, NY- 
ESO-1 and GBU4-5 and it was statistically significant for these antigens. The 
incidence o f cancer also increases with age and increased response o f 
antibodies to cancer related antigens with age could be a reflection o f cancer 
becoming more common with aging.
General autoantibody levels increases with age (Aho, 1980; Moscardi et al, 
1997). It has been shown that incidence o f benign autoimmune disease 
increases with age(Morganti et al, 2005) and levels o f immunoglobulins G,M
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and A also increases with age(Rink & Seyfarth, 1997). Although there are no 
previous studies on autoantibodies to cancer related antigens with reference to 
age, it is possible that as with benign autoimmune disease there is a true rise in 
antibodies to cancer specific antigens with age. If  this rise is a true reflection 
o f antibody response with age, this could be an important factor when setting 
the cut off for autoantibody tests in the future. Further follow-up o f these 
subjects is warranted to research this further, and as consent for this has been 
already taken from these subjects for the above, it could be undertaken in the 
future.
Autoantibody response to TAA’s was similar in both genders with all the 
antigens except CAGE showed no statistical difference between the two 
genders. To eliminate the effects o f other possible factors like age and 
smoking, over 500 subjects in each gender were matched for age (+/- 3 years) 
and smoking history. However, this also showed a significant difference for 
autoantibody response to CAGE antigen. CAGE is a cancer testes antigen and 
in normal individuals its expression is largely restricted to testes(Alsheimer et 
al, 2005). Antigen levels could be inherently elevated in males, and with 
genetic changes with age, they are no longer recognised as self and thus 
producing an elevated antibody response. With the limitation o f available data, 
this would require confirmation o f another normal dataset. Another possibility 
we have explored for the gender difference in CAGE is the imbalance in 
gender across assay runs. The PAS samples were assayed in two distinct time 
periods (period A and period B) and the gender ratio was not constant over 
these two sets, with the ratio for first period being M:F 1:11.6 and second
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period 1:0.4 respectively. The means o f OD for CAGE were very similar in 
period A but in period B there was an increase in males with an obvious 
difference in mean optical densities. This could suggest that the difference for 
Cage is not a consistent effect. Furthermore, when statistical adjustments were 
used to eliminative the effect o f  run difference, there was no statistically 
difference between the means between two genders for CAGE. Overall 
therefore the available evidence is that there is no difference in autoantibody 
response to cancer related antigens with gender which is what we anticipated 
. in the beginning. This is further interesting given the fact that there is increase 
in antibody response to benign autoimmune disease in females.
Autoantibody response to all cancer related antigens were consistently low in 
smokers. It is well known that smoking can produce a suppression o f immune 
response (Lu et al, 2007; Robbins et al, 2004). This could explain the 
relatively low antibody response in smokers. The rise in autoantibody response 
was more in the ex-smoker group compared to the other two groups with all 
the antigens except NY-ESOl suggesting the possibility o f rebound effect 
when smoking is stopped. To analyse further the rebound phenomenon o f  rise 
in AAB level after cessation following a period o f smoking, the year o f 
quitting for ex-smokers was extracted from the database. There was very little 
difference for most antigens back to 1970, but decades before that there was an 
observed increase in the mean AAb level for all antigens except SOX2. We do 
not have sufficient data to analyse how long the rebound phenomenon might 
last and there is no available literature at present to support this finding.
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Nine percent o f the subjects had personal history o f autoimmune disease. 
These subjects did not show any significant response to these cancer related 
antigens compared to those subjects without personal history o f  autoimmune 
disease. This data supports the previous report from our institute that the 
immune response to these cancer specific antigens which is measured by 
detections o f  IgG antibodies is antigen specific. A significant proportion of 
subjects who are screened for cancer would have autoimmune disease, and our 
study clearly shows that autoantibody levels to these cancer antigens are not 
altered in patients with autoimmune disease and their measurement to detect 
early cancer should reflect as for the rest o f the population.
Almost half the subjects either had first or other close relative with cancer. The 
autoantibody responses to cancer antigens were no different from those 
without family history o f cancer. We looked into subjects across all decades of 
life and did not focus on simply the older decades where the cancers are more 
prevalent. This is because we wanted to address whether family history per se 
was linked to the presence o f autoantibodies against tumour associated 
antigens as opposed to someone with a family history is actually developing 
cancer. These data show that on a population basis, just having family history 
o f cancer doesn’t make you more likely to have autoantibodies to tumour 
associated antigens. If a subject show an increased autoantibody response to 
these tumour associated antigens, it is more likely that this is due to them 
developing cancer themselves rather than being linked to their family history 
and warrant further diagnostic tests. However in subjects with specific 
mutation like BRCA1 or 2 this may not be the case, as you may get antibodies
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directly linked to the mutation. Mutation could lead to abnormal production of 
protein which could be recognised by our immune system as foreign. 
However, at what stage o f the genetic change these proteins become 
immunogenic and why some proteins are immune privileged rendering them 
not to be identified by the immune system is not clear. Although various 
theories have been proposed(Kazarian & Laird-Offfinga, 2011) including 
increased level o f expression or altered localization and post-translational 
modifications for the immunogenicity o f some antigens, it is clear that further 
research is required in this field.
Further research arising from this thesis would be to focus on following the 
individuals in this population based study to find out how many develop lung 
cancer and whether or not the autoantibody response matches in these 
individuals. This could also give us an idea as to the lead time from the tumour 
marker rise to the clinical presentation o f lung cancer. This is beyond the 
scope set out for this thesis.
Further research should be also possible with blood samples collected in this 
study to identify new antibodies which could improve the accuracy o f the 
present screening panel to aid in the diagnosis o f lung cancer. Further research 
should also focus on the development o f other panel against other common 
cancers given that these individuals are now being tracked on the cancer 
registry.
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Appendix 1- Consent form
H I The University of
JJ^ Nottingham
HEALTHY VOLUNTEER CONSENT FORM 
Population study o f  autoantibodies in peripheral blood 
The University of Nottingham & Oncimmune Ltd
The patient should complete the whole of this sheet herself. Please cross out as necessary
Have you read and understood the patient information sheet? YES / NO
Have you had an opportunity to ask questions and discuss the reason
for requesting a sample of your blood? YES / NO
Have all the questions been answered satisfactorily? YES / NO
Have you received enough information about the reasons for requesting
these samples? YES / NO
Who have you spoken to? Prof/Dr/Mrs/Mr.................................................
Do you understand that you are free to refuse to allow your blood to be
taken and used in the ways described in the information to patients sheet
without having to give a reason? YES / NO
Do you confirm that you have not been a subject in any other research study 
in the last three months which involved: taking a drug; having any invasive 
procedure (eg blood >50ml, endoscopy) or exposure to ionising radiation. YES / NO
Do you agree to?
• * 40mls (8 teaspoonfuls)/*100mls (20 teaspoonfuls) being taken? YES/NO 
(♦delete whichever you do not wish to give
• being contacted on one further occasion in the next 18 months? YES / NO 
Do you agree to allow your samples to be used?
• for research, development and production of blood tests as described YES / NO
• for any future such use as may be decided by the investigators YES / NO
Do you understand that any information provided in the questionnaire
will be kept confidential YES / NO
Faculty of Medicine & Health Sciences 
06/03/08
However relevant information may be made available in confidence to:
• regulatory bodies
• commercial companies
interested in any research findings or any tests or therapies produced by
the University of Nottingham and/or Oncimmune YES / NO
Do you understand and agree that research obtained involving your blood
may be published although you as an individual will not be identifiable? YES / NO
Do you agree to researchers accessing local and national cancer databases
in future to find out if you have or have not developed cancer at a future
time point? YES / NO
Do you agree to allow the researchers to pass on a sample of your blood 
in fUture to other researchers? -
• within the European Union YES / NO
• outside the European Union YES/NO
Do you understand you are relinquishing all right, title and interest in such
material to the University of Nottingham and/or Oncimmune and signing
away the rights to any discovery? YES / NO
Do you agree to this? YES / NO
Signature (patient)..............................................................  Date.......................
Name (in block capitals).............................................................................
I have explained the study and the above person has indicated their willingness to take 
part.
Signature (Consenter)...............................................  Date.............................
Name (in block capitals)................ .. ...................................... .........
Faculty of Medicine & Health Sciences 
06/03/08 '
Appendix 2- Health questionnaire
The University of
Population Study Questionnaire
Data: /  /
Nam«: (Flrst/Ml/Last) 
Address:
M F 
Sex: r  c
Data of Birth: (mm/dd/yyyy) 
/  /
Currant Occupation:
Sms kina History
Are you a  sm oker? Currently Previously C Never ?
fm ra n t  Smokers
di day
How long have you sm oked for?
On average  how m any c ig arettes do you sm oke ear
previous Smoker«
sch day?
When did you stop  smoking?
How m any y ears  did you sm oke for?
On av erag e, how m any c ig arettes did you sm oke e
PAS Questionnaire, Version 2 dated 12 February 2008
Page 1 of 3
Do you have benign b reast d isease? 
If yes, p lease specify
Yes r  n o  r
Do you currently have any of th e  following benign Autoimmune Disorders?
Rheum atoid arthritis Yes r No r Lupus Yes r No r
Scleroderm a (skin) Yes r No r Sogjerns syndrom e Yes r No r
W egener's granulom atotis Yes r No r D iabetes mellltus Yes r No r
H ashim oto's thyroiditis Yes r No r Graves' d isease Yes r No r
Coellac disease Yes r No c Crohn's disease Yes c No r
Ulcerative colitis Yes r No r Multiple sclerosis Yes <* No r
Gulllain-Barre syndrom e Yes r No r Addison's disease Yes r No r
Primary bilary sclerosis Yes r No r Sclerosing cholantltis Yes r No r
Autoimm une hepatitis Yes r No r G oodpasture 's syndrom e Yes r No r
exposure to  Radiation
Have you ev er been exposed to  radiation? Yes r  No r
If yes, w hat w as the  reason for th e  exposure?
How long w as th e  exposure for?
PAS Questionnaire, Version 2 dated 12 February 2008
Page 2 of 3
Pergonal History of Cancer
Do you have any personal history of cancer? Yes r  No r
If y e s , w hat type of cancer w as diagnosed?
W hat d a te  was this diagnosed (o r when w ere you 
Inform ed)?
W hat trea tm en t did you have?
Have you had a  recurrence of th is cancer a t  any tim e? Yes r  No
fam ily History of Cancer
Do you have any family history o f cancer? yes No
If yes please specify:
Family Member Type of cancer Age diagnosed
PAS Questionnaire, Version 2 dated 12 February 2008
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